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Abstract
Glioma is the most common and aggressive primary malignant brain tumour. Glioma is
typically treated with surgery followed by radio/chemotherapy. Even with aggressive
treatment, median survival time is expected to be ~12 to 15 months. Reoccurrence of glioma
is almost inevitable, further threatening the well-being of patients who have already endured
rigorous treatment. Therefore, it is paramount to choose the most effective therapy and to
accurately determine outcome as early as possible to provide optimum end-of-life care.
Tumours alter their metabolism in response to increasing energy demands, mainly through
increased glycolysis and accompanying lactate production. This increases production of other
acids and alters intracellular and extracellular pH. Hyperpolarized 13C magnetic resonance
spectroscopic imaging, is capable of measuring in vivo metabolism. Increased lactate
production in tumours can be probed by imaging the metabolism of hyperpolarized [113

C]pyruvate after injection. Similarly, extracellular pH can be mapped after measuring the

concentrations of H13CO3- and

13

CO2 after injection of hyperpolarized 13C bicarbonate. The

objective of this thesis is to investigate molecular changes in lactate production and pH
gradient in a rat glioma model. To accomplish this objective, three related projects have been
undertaken. For first project, a custom-made switch-tunable radiofrequency coil was
designed and constructed. This radiofrequency coil facilitated imaging 1H and

13

C nuclei

without any registration issues producing high signal-to-noise ratio imaging data. In the
second project, C6 glioma was implanted into brains of rats, which were imaged with
hyperpolarized [1-13C]pyruvate at days 7, 12, 15, 18, 21 and 24 after implantation. Between
days 10 and 15, rats received one of three therapies: radiotherapy, chemotherapy, combined
therapy or none. Significant early therapeutic response, measured as a reduction in the
lactate-to-pyruvate ratio, was observed for effective therapy. In the final project, the same
tumour model was used to study cellular pH gradient in tumours. Animals were monitored at
days 8, 12 and 15 after implantation using hyperpolarized

13

C bicarbonate to measure

intracellular pH and a chemical exchange saturation transfer method to measure intracellular
pH. Measured pH gradient in tumours showed a higher intracellular pH than extracellular
pH, which was the opposite of healthy brain tissue. These studies have demonstrated the
potential of hyperpolarized

13

C probes to promptly measure changes in tumour metabolism.
i

Early response assessment is important for identifying effective therapies and eliminating the
toxic effects of ineffective ones. This can potentially reduce treatment costs for expensive
and ineffective therapies and improve the quality of life for patients.
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13
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13
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Chapter 1
Introduction

1

1.1 Introduction to 1H Magnetic Resonance Imaging
In this section, general background information is provided for the magnetic resonance
imaging (MRI) methods relevant to this research. In particular, information regarding
nuclear spin, magnetization, RF pulses, relaxation, free induction decay, chemical shift,
k-space, spatial encoding, spin-echo and gradient-echo sequences, echo planar imaging
sequences and their applications will be provided. Further detailed explanation of those
topics can be found in several references. [1, 2]

1.1.1

Nuclear spin and magnetization

Conventional MRI involves exploiting the properties of the magnetic dipole moments of
protons (1H) as they interact with their environment for its imaging contrast. In the
absence of a magnetic field, the orientation of the magnetic dipoles of protons will be
random. However, in an external magnetic field, B0, the nuclear magnetic dipole
moments precess around the magnetic field direction at the Larmor frequency:
𝜔0 = 2𝜋𝛾𝐵0

Equation 1-1

where , is a nuclear property of the proton known as gyromagnetic ratio related to its
magnetic dipole moment (for 1H, 42.576  106 Hz T-1). As an ensemble of magnetic
dipoles precesses in the magnetic field, longitudinal spin-lattice relaxation will cause the
distribution of dipole directions to have a small alignment with the magnetic field. (In
MRI, the direction of this field is assumed to be along the z-axis.) This produces a net
longitudinal magnetization (M0), known as the thermal equilibrium magnetization, in the
direction of the magnetic field given by:
𝑀0 𝑧̂ =

𝜌0 𝛾2 ℏ2
4𝑘𝑇

𝐵0 𝑧̂ .

Equation 1-2

2

Here, ρ0 is defined as the number of protons per volume, ћ is known as the reduced
Planck constant (ℎ/2𝜋), k is the Boltzmann constant and T is the temperature of the
sample. The thermal equilibrium magnetization achievable at body temperature and
clinical field strength is small and is the major factor limiting the signal-to-noise ratio
(SNR) for MRI. In the human body, the average 1H concentration in tissue is large, ~88M
[1], which makes MRI possible for in vivo imaging with protons.

1.1.2

RF pulse and Relaxation time

In order to detect M0, it must be “tipped away” or perturbed from its equilibrium along
B0. This is achieved by application of a transverse radiofrequency (RF) magnetic field,
B1, oscillating at the Larmor frequency produced by an RF transmit coil. This excites M0
so that it precesses around the z-axis at an angle 𝛼, which is known as the flip angle. For
example, when an RF pulse is applied that produces a 90° flip angle, all the
magnetization is excited and precesses at the Larmor frequency in the x-y plane
orthogonal to B0. Components of the excited magnetization rotating in the transverse
plane (Mx and My) are referred to as the transverse magnetization, Mt, where
𝑴𝑡 (𝑡) = 𝑀𝑥 (𝑡)𝑥̂ + 𝑀𝑦 (𝑡)𝑦̂.

Equation 1-3

The transverse magnetization can be detected by an RF receive coil as an induced
sinusoidal voltage resulting from the oscillating magnetic flux through this coil. As this is
occurring, the longitudinal magnetization, Mz, is recovering asymptotically along B0 with
an exponential time constant given by spin-lattice relaxation time, T1, (or its reciprocal R1
= 1/ T1, the spin-lattice relaxation rate):
𝑀𝑧 = 𝑀0 (1 − 𝑒 −𝑡/𝑇1 ).

Equation 1-4

The exponential decay of the magnitude of the transverse magnetization, Mt, is governed
by the spin-spin relaxation time, T2, (or its rate R2 = 1/ T2):
𝑀𝑡 (𝑡) = 𝑀𝑡 (𝑡 = 0)𝑒 −𝑡/𝑇2

Equation 1-5
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The decay of transverse magnetization is due to interactions between spins that cause
individual spins to precess at different rates. Ultimately, Mt will be decay to zero and this
process is referred as dephasing. In addition to spin-spin interactions, local magnetic field
inhomogeneities caused by the inherent magnetic susceptibility of tissues and their
interfaces with air can cause the transverse magnetization to decay even faster. This is
characterized by the effective spin-spin relaxation time constant, T2* (or its rate, R2* = 1/
T2*).

Figure 1-1 Shows the magnetization, M0, after excitation by an RF pulse. M0 is perturbed
by an angle θ away from B0 (along the z-axis) by excitation of an RF pulse. The
longitudinal part of M0, Mz recovers asymptotically to the equilibrium value, 𝑴𝟎 𝒛̂ ,
defined by Equation 2 in a time governed by the spin-lattice relaxation time, T1. The
transverse component of the magnetization, Mt rotates in the x-y plane at the Larmor
frequency. The magnitude of Mt decays exponentially with the effective time constant
T2*.

1.1.3

Free induction decay and chemical shift

The oscillating signal with an exponentially decaying amplitude envelope acquired by the
RF coil after excitation is known as a free induction decay (FID). The frequency of the
FID deviates slightly from the 1H Lamor frequency since the protons precess in the local
molecular electron cloud in addition to the external field. This molecular distribution of
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electrons causes a shielding effect and ultimately a small but observable shift in the
Larmor frequency. This small shift is known as the chemical shift. Protons associated
with different molecules exhibit different chemical shifts. Magnetic resonance
spectroscopic imaging (MRSI) is a technique, which produces maps of the regional
distribution of molecules discriminated by their chemical shift. The FID can be converted
into a spectrum via a mathematical tool, the Fourier transform. The resulting spectrum
contains different spectral lines whose frequencies correspond to the various chemical
shifts of the imaged nuclei and whose amplitudes are proportional to their number
density. However, due to this small chemical shift in resonant frequency, nuclei with
different chemical shifts may appear to be displaced from their actual location. This
small, but important imaging artifact is referred as chemical shift displacement.[3]

1.1.4

k-Space and spatial encoding gradient

To encode spatial information in MRI, a linearly varying magnetic field (known as a
gradient) is applied across the imaging volume. This gradient can be applied along any
direction. When gradients are applied during excitation by the RF pulse, a specific slab of
the imaging volume can be excited instead of the entire volume. This procedure is known
as slice selection. After slice selection, a spatially encoded signal is collected in k-space.
k-Space is a frequency representation of the image and it can be transformed into an
image using an inverse-Fourier transform. Ideally, complete coverage of k-space is
required to produce a detailed image. Systematic application of gradients during signal
acquisition determine where data are accumulated in k-space (spatial encoding).
For instance, in two dimensions, gradients are used to spatially encode the MRI signal by
manipulating the signal frequency and phase. To collect a two-dimensional image, slice
selection is used to excite a slab of finite thickness along the z-axis. Spatial encoding of
the FID signal along the x-axis can be accomplished by applying a magnetic field
gradient along that axis during acquisition This is known as frequency encoding. Phaseencoding using short “blips” of a gradient applied along the y-axis. This alters the phase
of the precessing magnetization along that direction producing spatial encoding of the
MRI signal in the y-direction. Systematic application of the frequency and phase code
gradients and acquisition of the FID signals are controlled by a set of instructions known
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as the pulse sequence. After slice selection excitation, a phase-encoding gradient is
applied followed by acquisition of the FID signal with frequency encoding to acquire a
complete line of k-space. This needs to be repeated several times to acquire all lines of kspace data. The time between each RF excitation pulse is known as the time to repetition
(TR).

1.1.5

Spin-echo and gradient-echo sequence

The transverse magnetization can be used more efficiently be refocusing the dephasing
spins to create an “echo”. This echo can be induced by application of a 180° RF pulse
after the transverse magnetization reaches zero or a dephasing and refocusing gradient
during decay. The former technique is called a spin-echo sequence and the latter, a
gradient-echo sequence. Multiple echoes can be produced for each RF excitation of the
transverse magnetization so that several lines of k-space can be acquired before the
transverse magnetization is fully dephased to zero. The time between application of the
RF excitation pulse and when the echo is formed is known as the time-to-echo (TE).
Spin-echo and gradient-echo sequences and variants are the most frequently used
sequences in MRI due to their simplicity and utility.
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Figure 1-2 Simplified diagrams of a spin-echo and a gradient-echo sequence. Each line
shows application of the RF excitation pulse, the slice select gradient, x and y gradients.
Gp and Gf represent the duration of phase and frequency encoding gradients. Boxes
illustrate the trajectory of the 180° RF pulse, Gp and Gf in k-space.

1.1.6

Echo planar imaging sequence

Another method used in MRI is echo planar imaging (EPI). In this rapid imaging
technique, the entire k-space is acquired with a series of gradient echoes using only one
or a few RF pulses. EPI requires rapid application of strong magnetic gradients to quickly
fill k-space for a given image slice. This can be used to help mitigate image artifacts due
to subject motion. However, due to the extended series of gradient echoes, EPI is
weighted to T2* and is sensitive to field inhomogeneities. EPI is used to detect dynamic
changes in structure and contrast in cardiac imaging and perfusion imaging.

1.1.7
1.1.7.1

Application
T1-weighted and T2-weighted imaging sequences

Different tissues in the body have specific T1 and T2 values, which can be used to produce
image contrast between them. Using a spin- or gradient-echo sequence as described
above, imaging data can be acquired with either T1- or T2-weighting. To acquire an image
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with T1-weighted contrast, a gradient-echo sequence can be specified with a TR value on
the order of the tissue T1 value and a short TE value. TE and TR are chosen to minimize
the effects of T2* blurring and maximize the T1 contrast. Often a paramagnetic contrast
agent such as a gadolinium chelate is used to enhance the contrast of T1-weighted images.
These contrast agents significantly shorten the T1 of surrounding tissue, allowing
increased signal in T1-weighted images. To produce an image with T2-weighted contrast,
a spin-echo sequence can be used with a long TR value and a TE value on the order of
the T2 values. Spin-echo sequences negate the effects of T2* decay. TE and TR are chosen
to maximize the contrast related to T2 relaxation and minimize the effects of T1. Fluids,
such as cerebral spinal fluid have long T2 values which are manifested as regions of
increased signal in a T2-weighted image.

1.1.7.2

Dynamic susceptibility contrast imaging sequence

Dynamic susceptibility contrast (DSC) imaging is a technique that can be used to
measure perfusion. DSC exploits the change in image contrast due to a decrease in T2* by
the introduction of a paramagnetic agent such as a gadolinium chelate. It is common to
use a gradient-echo EPI sequence to generate a time series of DSC images. A series of
images are rapidly acquired during injection of the contrast agent. The temporal evolution
of the signal in individual voxels is examined across the time series as a result of the
bolus injection. This signal slowly increases from an initial minimum as the contrast
agent clears out of the tissue. Using this signal-time curve, the blood volume and flow
can be estimated on a pixel-by-pixel basis to produce tissue maps of these quantities. A
more detailed explanation and discussion of the application of DSC imaging is described
in reference [4].

1.2 Introduction of hyperpolarized 13C imaging.
This section describes some background information for hyperpolarized

13

C imaging.

This includes details regarding carbon-13 (13C), hyperpolarization by dynamic nuclear
polarization, hyperpolarized 13C-enriched metabolic probes and pulse sequences for data
acquisition of hyperpolarized compounds. More detailed explanations and descriptions
can be found in references [5-7].
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1.2.1

Carbon-13

Ordinary carbon-12 (12C) is ubiquitous in tissues. However, unlike protons, it is MR
invisible since it has no nuclear spin (magnetic dipole moment). Therefore,

12

C nuclei

cannot be aligned by an external magnetic field or manipulated by application of an RF
pulse. Among the isotopes of carbon, carbon-13 (13C) is a stable and naturally occurring
isotope that has a nuclear spin of ½. Thus,

13

C is visible with MRI; however, two major

issues complicate its imaging. First, the natural abundance of

13

C is 1.11% compared to

98.93% for 12C and 99.98% for 1H. [8] Since the signal is proportional to the number of
13

C nuclei in an imaging voxel, the detectable 13C signal is significantly lower than that of

protons. Secondly, the gyromagnetic ratio of

13

C is approximately 4 times less than that

of 1H. From equation 1, M0 is proportional to γ2. Furthermore, the FID signal induced in
the RF receive coil is also proportional to γ. Therefore, the MRI signal is proportional to
γ3 and it becomes quite evident that it is a significant challenge to perform MRI with 13C
nuclei. Although, it is possible to detect

13

C signal with MRI, it is very time consuming

and not particularly feasible for an in vivo study.
Table 1-1 Comparison between properties of 1H and 13C nuclei that affect the signal
strength in MRI.
1H

13C

Natural abundance

99.98%

1.11%

Gyromagnetic ratio (MHz/T)

42.577

10.705

1

0.0002

Nucleus

Relative signal strength

1.2.2

Hyperpolarized 13C

To counter the limited sensitivity of

13

C MRI, a few measures can be taken. Instead of

relying on the presence of endogenous naturally abundant (1.11%)
volume, highly-enriched
large dose of

13

13

13

C in the imaging

C-labelled molecules can be introduced. In practice, a fairly

C-labelled agents would need to be distributed throughout the tissue.

High-field MRI would also increase the observed

13

C signal but this is an expensive
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solution and practical limits exist on field strength. Hyperpolarization is another possible
solution to this problem. As the name suggests, hyperpolarization is an in vitro process to
enhance the magnetization of a sample by increasing the degree of alignment of the
contained nuclei beyond that achievable at thermal equilibrium (see Section 1.1.1). In
theory, any nucleus with non-zero nuclear spin can be hyperpolarized; however,
successful application depends on physical properties of the nucleus and its environment.
There are several methods of hyperpolarization but this thesis will focus on the dynamic
nuclear polarization (DNP) method used at the Robarts Research Institute.

1.2.3

Dynamic nuclear polarization

In principle, any liquid or solid containing molecules with MRI-sensitive nuclei can be
hyperpolarized by this method. The basic principle behind DNP is the transfer of spin
polarization from electron to nucleus. This transfer of spin polarization is mediated by
microwave irradiation. For this method, a stable radical is doped uniformly throughout a
liquid sample containing 100%-enriched 13C molecules. The magnetic dipole moment of
an electron is nearly three orders of magnitude larger than that of a proton and, at high
magnetic field strengths (3.35 T) and low temperatures (1.4 K), the unpaired electron of
the radical is nearly 100% polarized (aligned). By irradiating the pool of polarized
electrons from the doped radical with microwaves at a frequency near the electron spin
resonance (94 GHz), the electronic polarization can be transferred to surrounding nuclei
achieving a very high degree of polarization. [9] However, in this physical state (~1.4 K)
the frozen hyperpolarized liquids cannot be directly used for in vivo imaging.
Hyperpolarized compounds must be rapidly warmed to near body temperature, properly
buffered and free radicals removed for clinical use. This can be accomplished by quickly
mixing it with a super-heated buffer solution at high pressure. This process is referred to
as “dissolution” and it allows the buffered hyperpolarized solution to be rapidly prepared
for in vivo experimentation while preserving most of its magnetization achieved by DNP.
Using DNP, the MRI signal from hyperpolarized 13C liquids can be increased 10,000-fold
compared to thermal equilibrium. A detailed explanation of the method DNP is presented
in reference [6].
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Hyperpolarized 13C probes

1.2.4

Since carbon is the backbone of almost all biological molecules, it is possible to label
almost any biological molecule with
However, for hyperpolarized

13

C for use as a hyperpolarized contrast agent.

13

C probes to be of practical use, a few details need to be

considered. Firstly, the T1 values of these probes must be sufficiently long enough to
sustain their magnetization for MRI. Although hyperpolarization can greatly increase the
potential signal achievable from

13

C-enriched compounds, this signal rapidly disappears

as the magnetization decays to the thermal equilibrium magnetization by spin-lattice
relaxation governed by the T1 value. After a time interval equal to 3×T1, approximately
95% of signal is already lost. Before the sample is completely relaxed, the hyperpolarized
13

C probe must be transported to the MRI, injected and circulated through the vasculature

into the tissue of interest and rapidly imaged with MSRI. Furthermore, in vivo T1
relaxation is faster than in vitro T1 relaxation due to interaction with other molecules in
the vasculature and tissues. Secondly,

13

C nuclei in different positions in a molecule

likely possess different chemical shifts due to spin-spin couplings. This is known as
magnetic inequivalence. This leads to splitting of the

13

C signal producing a more

complicated nuclear magnetic resonance spectrum. Finally, as a probe of in vivo
metabolism the hyperpolarized agent must be delivered quickly and rapidly undergo
metabolism within the tissue of interest before imaging. As a result, the single most
limiting factor for effective imaging of hyperpolarized
of the

13

C nucleus. For

13

13

C imaging is the finite T1 value

C nuclei in small endogenous molecules, in vitro T1 values of

tens of seconds are possible facilitating imaging of their metabolism. In this thesis, the in
vivo use of two hyperpolarized

13

C metabolic probes will be presented: [1-13C]pyruvate

and 13C bicarbonate.

1.2.4.1

[1-13C]pyruvate

[1-13C]pyruvate is the most commonly used hyperpolarized

13

C probe for in vivo

metabolic imaging. Also, it is the first in-human hyperpolarized imaging probe. [10] 13C
pyruvate has been used for investigating metabolism in cardiac disease, prostate, breast
and brain cancers in different animal models including murine, rat, and pig models. [1114]

This broad use of pyruvate can be explained by its several advantages. First,
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pyruvate is a key metabolite at the center of an important metabolic pathway. Pyruvate
can be converted into carbohydrates, fatty acids, amino acids and metabolic energy.
Pyruvate is readily used by tissue with high metabolic activity. Commonly in cancer,
pyruvate is converted to lactate instead of contributing to the Krebs cycle. [15] Measuring
conversion between pyruvate and lactate is a straight forward process using
hyperpolarized 13C MSRI. In this case, the first carbon of pyruvate is labelled. If a study
of a pathway within the Krebs cycle is desired, then the second carbon of pyruvate is
labelled instead or as well. Secondly, the C1 of pyruvate has a relatively long T1
approximately 65 s at 3T. [16] This long T1 ensures that the magnetization of

13

C-

pyruvate is sustained during delivery to the tissues of interest and conversion into other
metabolites. Finally, pyruvate (with a single

13

C label) is detected as a single spectral

peak and its metabolic byproducts are well separated by chemical shift. This facilitates
accurate quantification of the concentration of the metabolite and its metabolic products.
In this thesis, [1-13C]pyruvate was used to probe metabolism to [1-13C]lactate. In terms of
chemical shifts, [1-13C]pyruvate is separated by 12 ppm from [1-13C]lactate and 4 ppm
from [1-13C]alanine.

1.2.4.2

13

C Bicarbonate

Another hyperpolarized
with

13

13

C probe relevant to this thesis is

13

C bicarbonate. pH imaging

C bicarbonate has been demonstrated in animal models of disease. [17]

Bicarbonate plays an important role in the pH buffer system. Tissues maintain pH
through a balance of bicarbonate and carbon dioxide (CO2) under the influence of
carbonic anhydrase. The ratio of bicarbonate and CO2 concentrations can be used to
estimate the pH of tissue using the Henderson-Hasselbalch equation as follows:
pH = p𝐾𝑎 +

[𝐻𝐶𝑂3− ]
[𝐶𝑂2 ]

.

Equation 1-6

Here, pKa (6.17) is the logarithmic acid dissociation constant and [HCO3-] and [CO2] are
the concentrations of bicarbonate and CO2 respectively. By labelling bicarbonate with
13

C, the ratio of bicarbonate and carbon dioxide concentrations can be measured using

hyperpolarized

13

C MRSI and maps of tissue pH are readily obtained. Since uptake of

bicarbonate by cells is slow compared to in vivo spin lattice relaxation of 13C bicarbonate,
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this method measures pH in the extracellular space. Unfortunately, the in vitro T1 of 13C
bicarbonate is only ~33 s, and ~ 10 s in vivo at 3T. [18] This is much faster relaxation
than for

13

C pyruvate. Therefore, imaging of hyperpolarized

13

C bicarbonate must be

performed quickly. The use of deuterium oxide instead of water as the solvent for the
dissolution media can significantly increase T1. [18] However, a large dose of deuterium
oxide could alter in vivo metabolism and at significant volumes is poisonous in animals.
[19] 13C bicarbonate and 13CO2 possess single spectral peaks, which are well separated by
a 36-ppm chemical shift.

1.2.5

Hyperpolarized 13C pulse sequences

Due to the limitation of finite T1 values of hyperpolarized

13

C compounds, MRI

sequences must be efficient. This includes imaging time and use of the
magnetization. The magnetization of the

13

13

C probe

C nucleus relaxes to thermal equilibrium in

tens of seconds and the DNP process requires approximately an hour to hyperpolarize
another sample for injection so that signal averaging as used in conventional MRI is not a
realistic option. Therefore, the magnetization of the hyperpolarized sample must be
excited with a series of small flip angle RF pulses to conserve the initial magnetization
for the acquisition of all k-space data. In addition, a short TR is required to preserve SNR.
Two imaging sequences were used in this thesis: free induction decay chemical shift
imaging and spectrally selective spiral imaging.
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Figure 1-3 Simplified diagram of FID-CSI sequence and its data analysis. a) Each line
shows application of the RF excitation pulse, the slice select gradient, x and y gradients
and signal. Gp represents the duration of phase encoding gradients. Box a) illustrates the
trajectory Gp and where the signal is stored in 3D k-space (with coordinate, kx, ky). Box b)
illustrates the 3D image-space (with coordinate, x, y) after 2D Fourier transformation
from 3D k-space. Each voxel a contains FID as shown in c). These FIDs can be
transformed to spectra as shown in d) by a 1D Fourier transform.

1.2.5.1

FID-CSI

Free induction decay chemical shift imaging (FID-CSI) is an enhanced version of a free
induction decay pulse sequence. After the RF excitation pulse and slice selection gradient,
phase gradients are added to encode spatial information. The resulting three-dimensional
k-space is a data matrix where the first and second dimensions represent spatial space of
kx & ky and the third dimension (spectral space) represents the spatially encoded FID of
that k-space coordinate. Once, the spatial portion of k-space is Fourier transformed into
image space, the remaining spectral dimension represents the FIDs of an individual
image voxel. The equation representing this FID is given here:
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∗

−𝑖𝛺𝑛 𝑡+𝜙𝑛 −𝑅2 𝑛 𝑡
𝑆(𝑡) = ∑𝑚
𝑒
.
𝑛=1 𝐴𝑛 𝑒

Equation 1-7

S(t) is the signal at time, t, m is the number of spectral lines with unique chemical shifts.
∗
An is the amplitude, Ωn is the frequency offset, ϕn is the phase offset, and 𝑅2𝑛
is the

effective spin-spin relaxation rate of spectral component, n. The number of spectral lines
depends on the number of metabolites in the spectrum and the number of inequivalent 13C
nuclei per metabolite. As the number of spectral lines becomes large, spectral overlap
becomes a potential difficulty. For the metabolites used in this thesis, their spectra are
largely well separated and signal parameters can be accurately estimated from fitting
equation 1-7 to the FID data. In particular, the amplitude of each metabolite in the FID is
extracted, which is used to estimate the relative amount of 13C metabolite in each imaging
voxel. This produces the same result as measuring the area of a spectral line. Voxel-byvoxel spectra can be produced by Fourier transformation and displayed as a function of
chemical shift from the peak (i.e. major) metabolite in ppm. The spatial resolution of the
spectral data is limited by the number of RF pulses and ultimately the total sample
magnetization. Since each k-space point requires an RF excitation pulse, even with small
flip angle excitation, only a limited k-space matrix can be acquired with sufficient SNR,
resulting in a relatively low-resolution image. The k-space matrix can be artificially
increased by zero-filling in spatial or spectral dimensions to increase the apparent
resolution after transformation. However, this does not actually improve resolution, but it
may be desired for aesthetic reasons. Often, a Gaussian filter is used to apodize the FID
signal to reduce high frequency noise in the resulting spectrum. Further mathematical
details regarding the relationship between the FID signal and resulting spectrum can be
found in reference [20].

1.2.5.2

Spectrally selective spiral imaging

This sequence was developed by Dr. Rolf F. Schulte (General Electric Healthcare) and is
described in detail in reference [21]. For this sequence, a spectrally selective RF
excitation pulse is employed. This RF pulse excites only a chosen metabolite(s) based on
its unique chemical shift(s). Then, the k-space data is acquired with a two-dimensional
spiral trajectory through k-space. Unlike, the Cartesian k-space acquisition described
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before, k-space is encoded in polar coordinates and then re-gridded into a Cartesian
coordinate system. The advantage of this method is that the regional distribution map for
each metabolite can be generated with a single RF pulse. Each metabolite is separately
excited and imaged serially. This is a very fast process so that even though data for
different metabolites are collected at slightly different times, relative metabolite
concentrations can still be assumed to be the ratios of the observed metabolite signals.
Furthermore, each metabolite map can be averaged to improve SNR until all the
magnetization has been expended or relaxed and the flip angle can be separately
optimized for each metabolite to further increase efficient use of the magnetization.
However, because only a narrow band of excitation frequencies is employed, it is
important to carefully calibrate the excitation frequencies and bandwidths to coincide
with the chemical shifts of the metabolites of interest.

1.3 Radiofrequency hardware
Details of the bespoke radiofrequency (RF) coil for

13

C/1H MRI are discussed in this

section. This includes consideration of RF materials and components, RF design, dualfrequency operation and transmit-only, receive-only (TORO) operation. Complete details
can be found in these references [22, 23].

1.3.1

RF coil concept

The purpose of the RF coil is to generate a uniform RF magnetic field, B1 for sample
excitation and to detect the resulting Mt. To maximize its efficiency for both excitation
and detection, an RF coil must resonate (be tuned) at the Larmor frequency of a particular
nucleus (i.e. 1H or

13

C). Also, the RF coil must be “matched” for a specific impedance

(usually 50Ω) The RF coil circuit can be represented as an array of lumped circuit
elements including resistors (R), inductors (L) and capacitors (C). The relationship
between L, C and resonant angular frequency (ω0) is described by the equation:
1

𝜔02 = 𝐿𝐶.

Equation 1-8

The geometry of the RF conductors within the RF structure and the choice of conductor
material determines the inductances and resistances. Then, capacitors are added to
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achieve resonance at a particular frequency. These capacitances can be considered as
tuning capacitors (Ct), since it is difficult to alter the inductance of the RF structure,
without changing its physical dimensions or materials. The impedance of the RF coil
must be matched to that of the rest of the RF transceiver chain including the transmission
lines that connects the RF coil to the excitation source and RF detector. Without proper
impedance matching, the measured FID will be attenuated by signal reflections. This is
accomplished by adding a circuit to transform the impedance of the RF coil to 50Ω.
Finally, a “balun” is added to the RF circuitry to unbalanced the RF signal. The balun
reduces RF current in the shields of coaxial cables and inputs. This provides the desired
optimum signal transmission and compatibility with the RF transceiver chain.

1.3.2

RF coil design

There are many RF coil designs suitable for MRI. The key objective is to design a circuit
that will provide an oscillating magnetic field perpendicular to B0. The simplest design is
a loop circuit. It is known as a surface RF coil, which has a very high sensitivity for a
limited imaging volume near the plane of the circuit loop. It is relatively easy to construct
and it is placed very near or against the imaging volume. In principle, the loop can also
be multi-turned or have a curved or complex topology to conform to the size and shape of
imaging volume. Surface coils are not used for RF excitation because they have poor RF
homogeneity even over a limited region of interest. However, the resulting limited field
of view makes them ideal RF receive antennae since they only detect noise from a small
volume. In general, the sensitivity of the surface coil drops off rapidly for distances
greater than the physical dimensions (i.e. diameter or length) of the RF coil.
Another common RF design is known as the birdcage RF coil, named for its physical
structure. As name suggests, this design is composed of two end rings connected by
several rungs resulting in a structure that looks like the skeleton of a birdcage. A birdcage
RF coil produces a very homogenous B0 field as the number of rungs employed are
increased. However, the sensitivity of this architecture can be severely influenced by
interactions (loading) of the coil with its imaging sample. Based on where the capacitors
are added to resonate the RF circuit, three distinct RF architectures can be identified. For
low-pass architecture, the capacitors are inserted into the rungs. For high-pass
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architecture, they are introduced between rung connections on both of the end rings.
When capacitors are added to end rings and rungs, this produces a band-pass architecture.
The choice of birdcage architecture largely depends on the resonant frequency as well as
the complexity and cost of the number of capacitors. Birdcage RF coils produce a B1 field,
which rotates in the transverse plane, perpendicular to rungs, when it is driven by two RF
signals with a 90° phase difference. This is known as quadrature operation, which also
increases the receive sensitivity of the RF coil by a factor of √2 compared to operation
with a single RF connection (port). Quadrature operation requires special hardware to
achieve the 90° phase offset between ports.

Figure 1-4 Simplified circuit diagrams of

C – 1H switch-tuned RF coil. a) shows the

13

switch-tuned coil operating as a band-pass bird cage coil (1H mode). Here, the PIN diodes
are reverse biased and the end ring capacitors are not bypassed by the diodes. b) shows
the switch-tuned coil operating as a low-pass bird cage coil (13C mode). Here the PIN
diodes are forward biased and AC current is bypassed around the end ring capacitors.

1.3.3

Dual-frequency RF coil

A simple RF coil is typically optimized to resonate at one chosen frequency. For
metabolic imaging with

13

C MRSI, it is desirable for the RF hardware to be capable of

operating at the Larmor frequencies of 1H to assess morphology and

13

C nuclei to map
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metabolism. In principle, this could be accomplished with separate RF coils; however,
changing RF coils is inconvenient and disturbs image registration between morphological
and metabolic data. The use of an RF system, which is simultaneously resonant at both
frequencies or that can be rapidly “switch-tuned” between frequencies eliminates the
need for subsequent image registration and its associated uncertainties and expedites data
collection.
RF architectures for multi-nuclear imaging are inherently more complex than singletuned RF systems and, as a result, often have reduced signal sensitivity and potential
losses in image SNR must be weighed against the advantages of image registration and
convenience. This research employed an RF system, which uses a switch-tuning strategy
to achieve the highest possible SNR for dual-frequency operation. This was accomplished
through the incorporation of PIN (PN junction with isolation region) diodes to change the
RF coil architecture between low-pass (13C) and band-pass (1H) operation (See Figure 14). In this scheme, the PIN diodes are placed in parallel with the end ring capacitors.
When the PIN diodes are forward biased by application of a DC bias, the end ring
capacitors are bypassed and the RF coil resonates at the

13

C Larmor frequency as a low-

pass RF coil. Reverse biasing the PIN diodes enables band-pass operation at the 1H
frequency. In addition, a

13

C RF surface coil was added for transmit-only, receive-only

operation to further improve 13C SNR.

1.3.4

Transmit-only, receive-only mode

As described in chapter 1.1.2, transmission and reception are usually accomplished by a
single RF coil. For transmit-only, receive-only (TORO) operation, a separate transmit RF
coil is used to excite the volume with homogenous B1 at a desired flip angle. The
important goal is to provide homogenous B1 such that the sample magnetization over the
entire imaging volume is excited to the same flip angle. Thus, a birdcage RF coil is
typically used for transmission. For reception, a separate receive RF coil is utilized to act
as a sensitive antenna to detect the resulting Mt. To achieve the highest SNR, a local
surface RF coil is chosen for its high sensitivity over a limited volume. One complication
with the TORO system architecture is coupling between transmit and receive RF coils. It
is desirable to only have the transmit coil resonant only during transmission and the
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receive coil only resonant during reception. For this switch-tuned RF system, decoupling
of the

13

C transmit and receive RF coils was accomplished by rapidly switching the

resonant frequency of the birdcage coil after transmission.

1.4 Glioma
A rat glioma model was used in this thesis as a prototypical solid tumour model to
evaluate pyruvate-to-lactate conversion measured by

13

C MRSI as a biomarker for

treatment response and demonstrate pH mapping in tumours. This section contains
information regarding background information for glioma, glioma therapy, tumour
metabolism and tumour pH.

1.4.1

Background of glioma

Glioma is a type of brain tumour that arises from glial cells. It is the most common
primary brain tumour and comprises 80% of all malignant brain tumours. [24] Gliomas
are graded between I ~ IV according to World Health Organization (WHO). [25] The
grading scale spans Grade I, categorized as a non-proliferating non-malignant tumour to
Grade IV considered a highly proliferating malignant tumour. The most common and
aggressive malignant glioma is glioblastoma, categorized as WHO grade IV.
Glioblastoma has very poor prognosis and a median survival rate of only 12 to 15
months. [26] Severe interventions such as surgical removal and radio/chemotherapy are
offered as treatments. Despite these efforts, this cancer inevitably recurs and further
undermines the well-being of patients. [27]

1.4.2

Glioma therapy

The most common treatment of glioma is surgical removal of the tumour (when it is
accessible) followed by radiotherapy and chemotherapy. For radiotherapy, a total of 60
Gy is delivered locally in 2 Gy fractions over 5 to 6 weeks. [28] Radiotherapy induces
double strand breaks of DNA causing cellular death. Surgical resection and conformal
radiotherapy is employed to preferentially eliminate tumour and spare healthy brain
tissue. This is followed by adjuvant chemotherapy. Typically for glioma, a dose of 150
mg/m2 of temozolomide (TMZ) in is given once daily for 5 days followed by 23 days
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without treatment. [28] TMZ is an alkylating agent that damages DNA by methylating a
specific site of DNA, which results in cellular death. Highly proliferating cells are
vulnerable to TMZ. However, its action is non-specific and its effects are not restricted to
tumours limiting its therapeutic window. TMZ also causes adverse side effects such as
nausea and vomiting. Other chemotherapeutic drugs such as antiangiogenic agents or
growth factor receptor tyrosine kinase inhibitors are also used in combination. [29]
Despite these aggressive and multimodal treatments, the median survival rate of patients
is increased to only 15 months. Considering the toxicity of these therapies, accurate and
prompt knowledge of treatment efficacy is paramount to guide therapeutic choice and
improve end-of-life care.

1.4.3

Tumour metabolism

The metabolic profile of tumours change during their progression. As mentioned in “The
Hallmarks of Cancer”, tumour metabolism is one of several key therapeutic targets [30].
The most notable change of metabolism exhibited by many tumours is an increased rate
of glycolysis and reduction of oxidative phosphorylation compared with other tissue even
with the availability of oxygen. This phenomenon was first observed by Dr. Otto
Heinrich Warburg and is referred to as the Warburg Effect. [31] In greater detail, the
uptake of glucose is increased by glucose transporters in many cancer cells. Glucose is
converted into pyruvate by several upregulated enzymes. The resulting pyruvate is
converted into lactate and produces oxidized nicotinamide adenine dinucleotide (NAD+)
from reduced nicotinamide adenine dinucleotide (NADH) by increased lactate
dehydrogenase (LDH) activity. [32] Compared to oxidative phosphorylation where
pyruvate is metabolized in the Krebs cycle in the mitochondria of cells to produce
adenosine triphosphate (ATP), the energy production by glycolysis is very inefficient
(measured as ATP production per molecule of glucose). As a result, tumour cells often
exhibit increased glucose uptake through increased membrane transport. [33] These traits
can be detected by several molecular imaging techniques. Positron emission tomography,
PET, using 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG), can quantitatively measure the
uptake of glucose in tissue. [34] Highly aggressive tumours such as glioma, exhibit
increased

18

F-FDG uptake. [35] As discussed in chapter 1.2.4.1, hyperpolarized

13

C
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pyruvate can also be used to measure metabolic conversion between pyruvate and lactate.
In tumours, where increased lactate production is observed, the application of therapy has
produced a commensurate decrease in lactate production. [7] Brain tissue is highly
metabolic reducing the contrast for brain tumours when assessed by

18

F-FDG PET.

Quantification of glioma metabolism with 13C pyruvate does not suffer this limitation.

Figure 1-5 Use of hyperpolarized [1-13C]pyruvate and

13

C bicarbonate for quantifying

tumour metabolism and tumour pH. [1-13C]pyruvate and 13C bicarbonate are delivered by
the vasculature. [1-13C]pyruvate is transported into the cytoplasm of tumour (or healthy)
cells by monocarboxylate transporter (MCT). Increased LDH activity in tumour cells
shifts the chemical equilibrium between pyruvate and lactate, creating a larger pool of
endogenous lactate in the cytoplasm. This results in a greater concentration of [113

C]lactate relative to [1-13C]pyruvate in tumour cells compared to healthy cells. Excess

protons and acids are pumped out of the tumour into the interstitial space. The pH of the
extracellular space is buffered by

13

C bicarbonate, which converts the excess protons to

water and 13C-labelled carbon dioxide.
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1.4.4

Tumour pH

pH is the scale measuring hydrogen ion activity in a given environment. Proteins are
often functional only within a limited pH range. [36] Therefore, tissues operate to
maintain pH both intracellularly and extracellularly. Within cells, hydrogen ions and
metabolic acids are generated, which decrease the intracellular pH (pHi). To balance this
acidic environment, hydrogen ions and cations are pumped out of the cell until the
electrochemical gradient of cell is balanced. [37] This results in acidification of the
interstitial space due to excessive hydrogen ions. The extracellular pH (pHe) is
maintained largely by the bicarbonate buffer system. Excess hydrogen ions are combined
with bicarbonate ions into carbon dioxide and water as shown here:
𝐻 + + 𝐻𝐶𝑂3− ⇄ 𝐶𝑂2 + 𝐻2 𝑂.

Equation 1-9

This process is facilitated by carbonic anhydrase and can be reversed if the surrounding
environment becomes too alkaline. Excess carbon dioxide and water are removed by the
vascular system. Similarly, within tumours, the pH also needs to be regulated. Since a
tumour is highly proliferative, it produces more metabolic acids. [32] To compensate, the
tumour often over-expresses transporters to transfer metabolic acids and cations into the
extracellular space. In the end, the pHi of the tumour cell becomes slightly alkaline due to
upregulated ion pumping. [37] The pHe of the tumour becomes acidic and without
functional and efficient vascularization, acidification of the extracellular space is
increased. This regional hypoxia resulting from insufficient vascularization can intensify
the aggressive proliferation of the tumour. [38] Compared to healthy tissues, which
exhibit pHe > pHi, tumours often show the opposite behaviour (pHi > pHe). [39] This
reversal of the pH gradient is an important a factor in the electrochemical gradient across
tumour membrane. Glioma is known to develop a very low pHe and this pH has been
correlated with its invasiveness. [38] Extracellular pH can be measured using
hyperpolarized

13

C bicarbonate as described in chapter 1.2.4.2. The intracellular pH can

be measured using an MRI method known as Chemical Exchange Saturation Transfer
(CEST). [40]
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1.5 Objectives and hypothesis
The objective of this thesis was to investigate molecular changes in tumour metabolism.
Assessment of tumour metabolism during tumour progression could potentially aid in
choosing patient-specific therapies. Hyperpolarized 13C imaging is an emerging technique
that is capable of non-invasively mapping the distribution of
probes. In this thesis, [1-13C]pyruvate and

13

13

C-labelled molecular

C bicarbonate were used to assess different

aspects of tumour metabolism in a rat model of glioma. We hypothesized that in vivo
hyperpolarized 13C imaging would be capable of sensitive and prompt assessment of the
therapeutic response of solid tumours ([1-13C]pyruvate) and to detect regional changes in
the pH gradient of tumours (13C bicarbonate).
The objective of chapter 1 is to provide the necessary introductory information for
chapters 2, 3 and 4. This includes 1H MRI, hyperpolarized

13

C MRSI, RF hardware and

glioma biology. In particular, sections 1.1 and 1.2 provide an explanation of the imaging
techniques and methods used in later chapters. A complete description was not possible
within the limitations of the journal manuscript format. Basic background information
required to understand the construction of RF coil in chapter 2 has been provided in
section 1.3. Finally, section 1.4 provides important biological aspects of the glioma
model that was used in this thesis.
The objective of chapter 2 is to describe the construction and evaluation of a novel
switch-tuned 13C – 1H RF coil, which was required for this imaging research. Special RF
coil technology is required to perform

13

C MRSI, in order to provide high sensitivity to

the 13C signal and facilitate co-registration between 1H and 13C imaging data. The design
and construction of a switch-tuned
tuned 1H and
tuned

13

13

13

C – 1H RF coil is discussed in chapter 2. Single

C RF coils have also been constructed and evaluated along with switch-

C – 1H RF coil. Improved signal sensitivity using the TORO mode is also

explored.
The objective of chapter 3 is to demonstrate the use of hyperpolarized 13C MRSI to assess
early therapeutic efficacy in a preclinical tumour model. A high rate of lactate production
from pyruvate is correlated with tumour proliferation. Using hyperpolarized [1-
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13

C]pyruvate as a probe, its conversion to [1-13C]lactate was quantified longitudinally in a

rat model of glioma. Early tumour response or lack of response to radiotherapy,
chemotherapy and combined therapies are compared with the absence of therapy in a
longitudinal imaging study using a C6 rat glioma model. Imaging results are validated
with histology at experimental endpoint.
The objective of chapter 4 is to longitudinally measure the intracellular/extracellular pH
gradient in a rat glioma model. CEST MRI was used for pHi measurement and
hyperpolarized

13

C-bicarbonate MRSI used for pHe measurement. Progression between

tumour volume and pH gradient is discussed in chapter 4. Histology (including
haematoxylin and eosin, HIF-1α and Ki-67 staining) is compared with tumour pH
gradient maps.
Chapter 5 summarizes the results from the three previous chapters and their contributions
towards molecular imaging of tumour metabolism in a rat model of glioma. This chapter
also includes future work for further expansion of these studies.
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Construction and evaluation of a switch-tuned 13C – 1H
birdcage radiofrequency coil for imaging the
metabolism of hyperpolarized 13C-enriched compounds
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and Timothy J. Scholl
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2.1 Introduction
The development of hyperpolarization technology to increase the magnetization of

13

C-

enriched endogenous compounds [1, 2] has enabled their use as contrast agents with
MRI. Cellular metabolism, which is often altered in diseases dictates the rate of uptake of
cellular substrates and their conversion for individual metabolic needs of the cell [3]. 13C
imaging and spectroscopy with MR can readily measure those rates and thereby quantify
cellular metabolism [4-6]. The inherent physical properties of the 13C-isotope such as its
limited natural abundance (1.1%) and its low gyromagnetic ratio (the

13

C gyromagnetic

ratio is four times less than that of 1H) results in a significantly lower MR signal [7]. The
use of endogenous compounds with highly enriched 13C compounds as metabolic probes
can overcome the natural abundance problem to a large extent; however, more
importantly,

13

C substrates can be highly magnetized (hyperpolarized) by dynamic

nuclear polarization (DNP) in vitro and then used as injectable agents to probe in vivo
metabolism [2].
Regional and time-resolved in vivo metabolic information can be determined using
hyperpolarized

13

C imaging and spectroscopy. Despite signal enhancement through

hyperpolarization, this information is limited in spatial or temporal resolution by the
amount of signal available due to the transient nature of the hyperpolarized state.
Metabolic information can be co-registered with tissue morphology obtained at higher
resolution using conventional proton MRI. The use of dual or switch-tuned RF hardware
that can image both nuclei without a change of RF coils or repositioning of the animal
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model simplifies the co-registration of metabolism and anatomy and makes this
registration essentially exact.
This study describes the construction and performance of a switch-tuned

13

C - 1H

birdcage radiofrequency (RF) coil that can be rapidly switched between anatomical
imaging mode (1H) and metabolic imaging mode (13C) by use of PIN (PN junction with
isolation region) diodes. To determine the utility of the switch-tuned
individual single-tuned 1H and

13

13

C - 1H RF coil,

C birdcage RF coils with identical dimensions were

constructed for a detailed comparison of imaging performance. A
surface RF coil was integrated with the switch-tuned

13

13

C receive-only

C - 1H RF coil exploiting its fast

frequency switching capability to enable transmit-only, receive-only (TORO) operation
for

13

C spectroscopy with improved sensitivity. Lastly in vivo

13

C spectroscopy and 1H

imaging were performed using TORO operation to demonstrate the practicality of this
hardware strategy.

2.2 Methods
2.2.1

Coil Geometry

All RF coils were constructed with the same physical dimensions and materials for
accurate comparison of imaging performance gauged by the observed signal-to-noise
ratio (SNR). The coil dimensions were chosen to accommodate an animal model up to
the size of a small rabbit. Each coil consisted of a birdcage resonator and a shield. The
resonator was constructed on a cylindrical acrylic tube, 88.9 mm in outer diameter (OD)
by 266.7 mm in length. The thickness of the coil form was 3.2 mm. The RF shield (356
mm long, 165 mm OD) was constructed on a separate cylindrical acrylic tube and two
nylon rings were used to concentrically locate it with respect to the resonator. These rings
also served to fasten the coil assembly to a rail system that was used to position the
hardware in the scanner.

2.2.2

Resonator Circuit

Three eight-rung birdcage resonators were constructed: a single-tuned

13

C (32.115 MHz

at 3 Tesla [T]) low-pass resonator, a single-tuned 1H (127.728 MHz at 3T) band-pass

30

resonator and a switch-tunable combined 13C low-pass and 1H band-pass resonator. Selfadhering, copper foil tape (12.7-mm-wide by 0.07-mm-thick) was fitted into grooves,
which were accurately machined into the acrylic forms and the copper conductors were
soldered together to form the basic eight-rung resonator geometry. The length of each
rung was 101.6 mm and the diameter of the end rings was 87.3 mm. High-Q capacitors
(Q > 2000, Working voltage: 500 V, American Technical Ceramics) were used to
resonate the coil. The capacitances were initially determined to a few percent by software
(Birdcage Builder Version 1.0 Software, College of Medicine, Penn State Hershey) and
later refined as resonators were fine-tuned [8]. The switch-tuned 13C - 1H resonator
included PIN diodes (Micro-semi UM9415) in parallel with each of the capacitors on the
end rings. The PIN diodes were biased through a network of 10-mH RF chokes (Bourns
4612-RC).
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Figure 2-1 Simplified circuit diagram of the switch-tuned

13

C - 1H RF coil. The

capacitors on the end rings and rungs had slight variations in value. The switch-tuned 13C
- 1H RF coil had a total of four RF connections, a pair for each frequency of operation.
A simplified circuit diagram of the switch-tuned 13C - 1H RF coil is shown in Figure 2-1.
The RF circuitry consisted of eight rungs and four matching networks. Each frequency
matching network was 90° apart in phase from each other. The birdcage coil is well
documented in the literature [9]. An eight-rung birdcage RF coil provided a homogenous
B1 field while minimizing complexity of construction [10]. The single-tuned 13C coil is a
low-pass birdcage design that uses lower-value capacitors. The single-tuned 1H coil and
switch-tuned 13C - 1H RF coil used a band-pass birdcage circuit. The band-pass or hybrid
birdcage circuit is a combination of low-pass and high-pass birdcage circuitry, which
conveniently lends itself to a switching scheme between these two resonator geometries.
Switch-tuning was accomplished by controlling the RF impedance of the PIN diodes
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using a DC bias. The method of switch-tuning resonator frequencies for different nuclei
using PIN diodes had been previously described for two relatively closely spaced Larmor
frequencies 127.728 MHz (1H at 3T) and 97.302 MHz (3He at 3T) using band-pass
geometry [11]. In that RF system, the relatively small frequency shift was achieved
without a complete change of the resonator geometry.
Bias current to the PIN diodes was DC-choked to confine RF current to the resonator.
Careful use of twisted-pair cable for bias currents and use of RF chokes suppressed any
RF noise coming from the bias supply or from pickup along the cables. Impedance
matching circuits and baluns were chosen to use convenient values of capacitance and
inductance. All coils were first tuned while loaded with an appropriate phantom in their
shields and then slightly re-tuned at the scanner for optimum signal reception.

2.2.3

Matching Circuitry Baluns

Separate impedance matching circuits and baluns (balanaced→unbalanced) were used for
each frequency. Each coil was matched to 50  and “unbalanced” at a particular
frequency to reduce RF current in the coaxial shield [10]. The

13

C frequency was

matched with a  matching circuit and unbalanced with an LC balun. The 1H frequency
was matched with a capacitive matching circuit and unbalanced with a cable-trap balun.

2.2.4

Shield

The shield was comprised of strips of overlapping aluminum tape. Continuous strips of
self-adhering tape (330 mm long by 25.4 mm wide by 0.13 mm thick) were oriented on
the cylindrical form in a direction along the axis of rotation. Each strip of aluminum tape
overlapped the previous layer in the circumferential direction by 6 mm and was separated
with a layer of insulating Kapton tape.

2.2.5

RF Coil and Animal Support

The RF coils and animal tray were supported by a pair of non-conducting glass-fiber
reinforced plastic rails. These rails were located by plastic struts fixed to a platform that
was designed to fasten onto the patient bed of a GE Healthcare MR750 3T MRI scanner
(GE Healthcare, Waukesha, WI). All the components of the rail system and platform are
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MR compatible. A custom-built animal bed could be slid along the rail system and locked
at a specific longitudinal position. The animal bed provided delivery and recovery of
anesthesia through a nose cone and was heated by water (40°C) circulating through
internal channels to keep the animal warm under anesthesia during imaging experiments.

2.2.6

Surface Coil

A rectangular (91.0 mm by 90.0 mm)

13

C surface RF coil was used for signal reception

only. It was constructed on a curved acrylic form with an OD of 56.3 mm. The circuit
was actively detuned during RF transmission using a DC bias applied to a PIN diode.
Capacitive matching was used to match the coil to 50  and a cable trap balun was used
to eliminate shield currents.
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Figure 2-2 Detailed schematic of the RF configuration for transmit-only, receive-only
operation of the switch-tuned 13C - 1H RF coil. The T/R switch provided an RF transmit
pulse including a DC offset bias during transmission. The RF pulse was applied to the 13C
quadrature hybrid circuit, which drives the switch-tuned

13

C - 1H RF coil in quadrature

operation. In a parallel circuit, a tank circuit filtered AC current from the transmit pulse.
The resulting DC bias from the transmit pulse (present only during RF transmission) was
used to trigger the MOSFET circuit to supply DC current to bias the PIN diodes of the
RF coils.
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2.2.7

Power Supply and Switching Circuit

Active frequency switching and detuning of the RF coils during TORO operation was
accomplished by application of DC biases to the PIN diodes. A metal-oxidesemiconductor field-effect transistor (MOSFET) circuit (see Figure 2-2) was used to
control current from an Agilent U8002A power supply. During transmit/ receive (T/R)
operation of the switch-tuned RF hardware in 1H mode, the PIN diodes were reversebiased to prevent the RF current from biasing the end-ring diodes and detuning the
resonator.

2.2.8

Imaging Phantom

Two imaging phantoms were used to calibrate and test the coils. A rat-sized phantom was
constructed using a cylindrical container, 57.5 mm in diameter and 127.0 mm in length
with two separate coaxial compartments. The inner compartment held three glass vials
containing different

13

C-enriched compounds: [1-13C]sodium acetate,

13

C-urea, and [1-

13

C]pyruvate. The outer compartment was filled with 0.15-mmol/L MnCl2 in 0.9% saline

solution for coil loading. This phantom was designed to roughly mimic a rat model after
13

C metabolite injection. The second phantom consisted of a 5-mL plastic vial, containing

7-mol/L [1-13C]sodium acetate. Gd+ contrast agent was added to the sodium acetate
phantom to achieve a T1 of less than one second.

2.2.9

Coil Calibration

All the coils have been interfaced to the GE 3T MRI scanner. The
was used to calibrate 1H imaging and the
calibrate

13

13

13

C/1H rat phantom

C sodium acetate phantom was used to

C imaging and spectroscopy. Calibration of tip angles was determined by

adjusting the transmit gain to obtain a 90° pulse with the phantoms.

2.2.10 Phantom Imaging
For 1H images, two-dimensional (2D) coronal images of the phantoms were acquired
with a 128-mm  128-mm field-of-view (FOV) and 40-mm slice thick-ness resulting in a
0.5-mm-per-voxel in-plane resolution. A fast gradient-recalled echo (FGRE) sequence
was used with the following parameters: repetition time (TR) = 34 ms, echo time (TE) =
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4.1 ms, flip angle, α = 90° and 16 averages. For 13C imaging, the in-plane resolution was
reduced to 1 millimeter over the same field of view (FOV) and with the same slice
thickness as the coronal 1H images. Images of the phantoms were acquired using a broadbanded FGRE (bbFGRE) sequence with TR = 34 ms, TE = 2.3 ms, α = 90° and 64
averages. Image SNR was calculated with MATLAB code using the dual acquisition
method [12]. In addition, 13C spectra of the sodium acetate phantom were acquired using
a free induction decay chemical shift imaging (FID-CSI) pulse sequence with TR = 1000
ms, α = 90° and 64 averages.

13

C spectra SNR were analyzed using SAGE 7.7 (GE

Healthcare, Waukesha, WI, USA).

2.2.11 B1 Mapping
Using the

13

C/1H phantom, a 3D B1 map with 2-mm isotropic resolution was obtained

with a noninverting double-angle Look-Locker pulse sequence [13] (TR = 3.7 ms, 16
echo trains, nominal flip angle, α = 6° and 8 different TIs per angle). B1 maps were
reconstructed from raw data using dedicated software written in MATLAB (Mathworks,
Natick, MA).

2.2.12 Hyperpolarization
Trityl radical (OX063, GE Healthcare) was added at 15 mmol/L to

13

C-enriched (99%)

[1-13C]pyruvic acid (Cambridge Isotope Laboratories, Andover, MA). Approximately 25
mL of the mixture was hyperpolarized at 1.4 K and 3.35T using a HyperSense DNP
apparatus (Oxford Instruments Abingdon, Oxfordshire, UK). After approximately 45 min
of polarization, the hyperpolarized sample was rapidly thawed and diluted with a
buffering solution producing an 80-mmol/L [1-13C]pyruvate solution buffered to a pH of
~7.6 with a liquid-state polarization of ~15% [14]. Approximately 3 mL of the [113

C]pyruvate solution was gathered in a syringe and rapidly transferred to the MRI for

imaging.

2.2.13 Animal Imaging
Male Wistar rats were used for the in vivo experiments. One million C6 rat glioma cells
were implanted in the rat brain using a stereotactic frame. During the imaging session, the
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rat was anesthetized using isoflurane and warmed by a heated animal bed to maintain
body temperature. Rat breathing and temperature were continuously recorded using a
small animal monitoring and gating system (S.A. instruments, Stony Brook, NY). Axial
T2-weighted 1H images of the rat brain were initially acquired using a fast-spin echo
sequence with a 80-mm by 80-mm FOV, 0.3-mm isotropic resolution, 3-mm slice
thickness, TR = 4000 ms, TE = 85 ms, 16-echo trains and 9 averages. The buffered
hyperpolarized [1-13C]pyruvate solution was injected through the tail vein catheter in a
13

single 12-s bolus injection. Twenty-five seconds after the start of injection,

C spectra

(axial plane, 12 by 12 spectral imaging matrix, TR = 80 ms, bandwidth = 5 kHz, 2048
pts, α = 10°) were acquired using a 2D FID-CSI pulse sequence with a 60-mm by 60-mm
FOV, slice thickness ≈ tumour extent. All animal procedures were approved by the
University Council on Animal Care, Animal Use Subcommittee.
Table 2-1 Network analyzer (Agilent E5061B) measurements of RF coil performance*
Single-Tuned Coil
Nucleus
Resonant frequency (MHz)†

1

H

13

C

Switch-tuned Coil
1

H

13

C

127.74

32.15

127.70

32.09

Reflected signal (dB) †

-44.0

-37.5

-40.6

-40.9

Quality factor

200

183

109

45

Isolation (dB)

-22.8

-42.5

-20.9

-44.0

* All RF coils were preloaded with the animal tray and a 13C/1H phantom.
Resonant frequency, reflected signal and isolation were measured using a
5-MHz frequency window. The RF coil quality factor was measured with
the network analyzer using separate transmitting and receiving RF coils
placed outside and inside (respectively) of the single- and switch-tuned 13C
- 1H RF coils.
† Averaged value for both channels.

38

2.3 Results
2.3.1

Initial Coil performance

Benchtop measurements of the coil performance are shown in Table 2-1. All coils were
preloaded with the animal tray and

13

C/1H phantom. The resonant frequencies were

within 30 kHz of nominal values at 3T. Quality factors were systematically lower for the
switch-tuned

13

C - 1H RF coil compared with the single-tuned RF coils (for proton 109

vs. 200, for carbon 45 vs. 183). Isolation between quadrature channels was very similar
for the switch-tuned

13

C - 1H RF coil and single-tuned RF coils, but

13

C isolation was

much greater than that observed for 1H. 13C transmit power for the switch-tuned 13C - 1H
RF coil was higher than the single-tuned 13C RF coil.

Figure 2-3 1H (1H FGRE) and

13

C (13C bbFGRE) images of a rat-sized 13C/1H phantom

were acquired with single- and switch-tuned 13C - 1H RF coils for SNR comparison. c,f:
13

C spectra (13C FID-CSI Spectrum) of a thermally polarized [1-13C]sodium acetate

phantom were also acquired using both RF coils. The percentage SNR for the switchtuned

13

nuclei.

C - 1H RF coil was with respect to the single-tuned coil for either 1H or

13

C
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2.3.2

SNR Comparison Using Phantoms

Images of phantoms acquired from the three coils are shown in Figures 2-3 and 2-4. For
1

H operation, the image SNR observed from the switch-tuned 13C - 1H RF coil was 87%

that of the single-tuned 1H RF coil. For

13

C operation, the SNR observed using the

switch-tuned 13C - 1H RF coil was 56% that of the single-tuned 13C RF coil. Operation of
the switch-tuned

13

C - 1H RF coil in TORO mode with the

showed the highest SNR determined from

13

13

C surface receive coil

C images of our phantoms. The resulting

image SNR was increased by a factor of 2.35 for TORO operation compared with singletuned

13

C T/R operation. Additional SNR comparisons from

13

C spectra are shown in

Figure 2-3c and f. For 13C spectroscopy, the SNR measured using the switch-tuned 13C 1

H RF coil (T/R operation) was 46% of that observed from the single-tuned 13C RF coil.

Figure 2-4 Comparison of 13C images with a thermally polarized [1-13C]sodium acetate
phantom acquired using three different RF coils. SNR measurements were normalized to
100% for the single-tuned 13C RF coil.

2.3.3

B1 Homogeneity

Figure 2-5 illustrates a T1-weighted 1H image, B1 map and its respective B1 profile. The
mean observed flip angle was 5.66° with standard deviation of 0.4327 for a nominal
value of 6°. The B1 profile revealed only a small amount of Gibbs ringing and RF
inhomogeneity over the entire volume of the phantom.
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Figure 2-5 B1 map obtained from the switch-tuned

13

C - 1H RF coil with a phantom

(shown at left). Nominal flip angle, α was 6°. The B1 profile was acquired axially through
the phantom at the red line shown on the B1 map.

2.3.4

In Vivo Imaging

A summed spectrum from individual rat brain voxels is shown Figure 2-6a. Individual
13

C-spectra overlaid on a T2-weighted 1H image of a rat brain glioma are shown in Figure

2-6b. These spectra contained five relevant spectral components (numbered 1 to 5 from
left to right); lactate, pyruvate hydrate, alanine, pyruvate, and bicarbonate. Spectral
quantification and image registration was carried out using SAGE 7.7. The boundary of
the tumour region was highlighted in red and voxels containing tumour exhibit higher
lactate to pyruvate ratio (Lac/Pyr) than healthy tissue voxels.
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Figure 2-6 Summed

13

C spectrum (left) and individual

13

C spectra (right) overlaid on a

T2-weighted 1H image of a rat’s head. a) Relevant spectral peaks labeled 1 through 5
(summed from individual spectra at right) were respectively: lactate, pyruvate hydrate,
alanine, pyruvate and bicarbonate. b) A brain tumour was outlined in red. Notice the
elevated lactate-to-pyruvate ratio in tumour voxels compared with healthy brain tissue.

2.4 Discussion
All three birdcage coils were geometrically identical and share common circuit
components and construction methods that had been optimized for 50  impedance.
Baluns were added to each matching network to eliminate RF current in the coaxial
shields and prevent unwanted common mode currents. Suitable biasing of the diodes
produced a switchable capability that is used to rapidly alter the resonator geometry from
band-pass configuration (1H) to low-pass configuration (13C). When the switch-tuned 13C
- 1H RF coil was forward biased, PIN diodes on rings of the band-pass birdcage resonator
presented a low-impedance path to RF, effectively eliminating the ring capacitors
resulting in a low-pass RF coil that resonates at the
when the switch-tuned

13

13

C Larmor frequency. Conversely,

C - 1H RF coil was reverse biased (or no DC is applied), the

intrinsic capacitance of the PIN diodes in parallel with the ring capacitors, produced a
band-pass birdcage resonator at the 1H frequency.
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Benchtop measurements of the quality factor for each coil were obtained as an
assessment of coil sensitivity [10]. Reflected signal strength from the RF coil provided a
secondary determination of coil performance, assessing coil matching. In initial coil
performance testing, the reflected signal strength did not vary much from coil to coil.
Yet, when the quality factor was considered, the switch-tuned 13C - 1H RF coil has poorer
performance than single-tuned RF coils for both nuclei. This translated to reduced SNR
during imaging.
There were a few factors that contribute to reduction in quality factor of the switch-tuned
13

C - 1H RF coil. Use of PIN diodes could cause dissipation of the RF energy stored in

the resonator circuit. During forward biasing, the RF resistance of the diodes was low but
not negligible. When reversed biased, a PIN diode operated as a low-Q capacitor in
parallel with the ring capacitors. The junction capacitance of the PIN diodes was
nominally 4 pF, which is approximately 10% of the capacitance of the ring capacitors.
The addition of bias lines and RF chokes may also reduce the efﬁciency through
imperfect RF blocking. Increased complexity of the resonator due to the addition of extra
components for switch-tuning could lead to asymmetries in the resonator circuit that are
difﬁcult to correct.
Individual PIN diodes were forward biased with a current of 0.375 A. With this bias
current, the nominal resistance of the PIN diodes at 32.1 MHz was measured to be 0.5 .
Most of the power supplied by the bias power supply was dissipated in the RF chokes
which have a DC resistance of 1.5 . This resulted in a small amount of heating of the
RF coil structure during 13C imaging. In practical use, the coil was largely operated in 1H
mode and this heating was insigniﬁcant considering the proximity of the heated animal
bed inside the RF coil.
Image SNR and spectral SNR were compared between coils. Based on benchtop
measurements, reduced SNR for both frequencies was expected. Quality factors of the
switch-tuned

13

C - 1H RF coil were lower than those measured for the corresponding

single-tuned RF coil. For proton imaging, benchtop measurements of the Quality factor
showed a 46% reduction for the switch-tuned 13C - 1H RF coil compared with its single-
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tuned RF coil. Comparisons of proton SNR between these coils yielded a loss of 13% for
the switch-tuned conﬁguration. For comparisons at the
of the switch-tuned

13

13

C frequency, the Quality factor

C - 1H RF coil was only 25% that of the single frequency coil

resulting in a larger reduction of imaging SNR. An SNR loss of 45% for the switch-tuned
13

C channel was observed compared with the

were expected to drop for the switch-tuned

13

C single-tuned RF coil. Coil efﬁciencies

13

C - 1H RF coil due to the added losses of

extra necessary circuit components.
Modiﬁcations to the switch-tuned 13C - 1H RF coil were investigated to improve SNR. RF
chokes with different inductances were investigated; however, these changes did not
affect the

13

C SNR. No signiﬁcant SNR improvement was noticed by increasing the DC

bias current beyond the typical value that was required for
interesting that it is possible to ﬁne-tune the matching of

13

13

C operation. It was

C coils using the DC biasing

current. The exact mechanism was unknown, but it was likely linked to small corresponding changes in the PIN diode resistance. This characteristic is also observed when
the coil is reverse-biased to 1H mode but the amount of ﬁne-tuning of the 1H frequency
during reverse biasing is not very signiﬁcant in comparison to that achievable with
variations of forward bias current.
B1 homogeneity was another important factor for an RF coil. Application of uniform RF
energy across a sample is essential for some RF pulse sequences [10] and important for
quantiﬁcation of the spectroscopic data. For a coil possessing an inhomogeneous B1 ﬁeld,
an RF pulse would excite a sample with a non-uniform ﬂip angle. The switch-tuned 13C 1

H RF coil displayed a homogeneous B1 ﬁeld for the proton channel across a large ﬁeld of

view. The measured ﬂip angle was very close to the expected value of 6° with a small
measurement standard deviation. The B1 proﬁle demonstrated a small amount of Gibbs
ringing artifact at the edge of phantom boundary. Although not measured in this work, it
would be expected that the 13C B1 ﬁeld was similar to that of the proton [15].
Detailed information about TORO operation of RF hardware had been previously
described [16]. TORO operation takes advantage of the highly sensitive localized

13

C

surface RF coil and homogeneous transmission ﬁeld. The 13C surface RF coil and switch-
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tuned

13

C - 1H RF coil were precisely tuned and matched with the position of the

13

C

surface RF coil ﬁxed at the center of the birdcage coil with a suitable loading phantom.
During TORO operation, transmit and receive RF coils must be alternately tuned/
detuned during transmit and receive phases. This was accomplished by application of a
DC bias current to PIN diodes in the RF hardware circuitry. For imaging, a DC bias
current was applied during RF transmission, which switches the 13C - 1H birdcage RF coil
to resonance at the

13

C frequency and simultaneously detunes the surface RF coil. After

transmission, the absence of this bias shifted the resonant frequency of the birdcage coil
to the proton frequency. This effectively decoupled the birdcage and 13C surface RF coils
and enabled reception of the 13C surface RF coil at the 13C frequency. For 1H imaging, the
small 13C surface RF coil did not couple signiﬁcantly to the birdcage resonator operating
at the 1H frequency during either transmission or reception. Therefore, no other
decoupling circuitry was required. Bias current provided by the MRI scanner was limited
and not sufﬁcient to bias all the required PIN diodes. For this work, the DC bias from the
scanner was used to control a fast MOSFET switching circuit that modulated the current
from an auxiliary DC power supply, effectively increasing the available bias current. In
theory, TORO operation could also be implemented at the 1H frequency with an
appropriate surface RF coil but this was not undertaken for this work.
To illustrate the capability of the switch-tuned

13

C - 1H RF coil, an in vivo experiment

was conducted. After injection of hyperpolarized [1-13C]pyruvate, the SNR for the
summed spectra was easily sufﬁcient to determine the amount of pyruvate and its
metabolites observed in the rat model of glioma. The ratio of observed Lac/Pyr was often
used as a measurement of local hypoxia to study diseases such as cancer [17]. However,
other metabolites such as alanine or bicarbonate could be also monitored [17]. The high
SNR resulting from TORO operation permitted quantiﬁcation of the Lac/Pyr in
individual voxels of the rat brain and tumour yielding regional information of tumour
metabolism. Tumours manifesting signiﬁcantly higher Lac/Pyr were well documented in
the literature and this biomarker could be used to identify early onset of tumour
progression [18] or tumour response to therapy [19, 20]. Other relevant information such
as perfusion and angiography could be acquired using 1H imaging. Exact co-registration
of 1H and

13

C data facilitated unambiguous evaluation of the higher resolution 1H data
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with tissue metabolism obtained by

13

C imaging. In the future, TORO operation of this

RF coil will be used to monitor various animal disease models with hyperpolarized

13

C

substrates.
In conclusion, this study described the construction of a switch-tuned

13

C - 1H birdcage

RF coil and compares its imaging performance with identical single-tuned RF coils as a
true measure of its utility and to measure potential SNR losses due to its more
complicated circuitry. Imaging comparisons measured a reduction in observed SNR for
the switch-tuned 13C - 1H RF coil compared with identical single-tuned RF coils at either
frequency. However, for TORO operation with a

13

C surface RF coil, the

13

C SNR was

4.2 times higher than ordinary T/R operation of the switch-tuned 13C - 1H RF coil. The B1
ﬁeld proﬁle for 1H imaging provided uniform RF excitation over a 13-cm FOV. A dual
frequency or switch-tuned RF coil permits data acquisition at two distinct frequencies
(i.e., for different nuclei) with exact image co-registration for those images. But unlike a
dual frequency RF coil, the integration of a 13C surface RF coil with the 13C - 1H switchtuned RF coil for TORO operation was relatively simple (due to shifts of the resonator
frequency) producing signiﬁcant improvements in imaging SNR. This switch-tuned 13C 1

H RF birdcage coil operating with a

13

C receive-only surface RF coil in TORO mode

was extremely useful for analyzing in vivo models where anatomic information of 1H
images provides a high-resolution background against which to evaluate regional
metabolic information obtained by 13C spectroscopy or imaging with enhanced SNR.
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3.1 Introduction
Brain cancer is a challenging disease with very poor prognosis and outcomes. The most
prevalent form of malignant brain tumours is glioma, which arises from glial cells.[1]
While there are aggressive therapies available (i.e. surgical resection, radiotherapy, and
chemotherapy), patients diagnosed with the most aggressive (grade IV) malignant glioma
have a disappointing five-year survival rate of 5.1%.[2] Despite aggressive treatment,
these tumours almost inevitably recur.[3]
Advances in imaging techniques help radiologists to noninvasively detect and assess
brain tumours. Magnetic resonance imaging (MRI) is the preferred clinical diagnostic
tool for brain tumour detection,[4] yet it is still challenging to observe both the
therapeutic response and efficacy during the course of the treatments. Because
radiotherapy and chemotherapy affect tumours at the molecular level (DNA damage,
blocking protein/RNA), phenotypical changes (tumour size, diffusion, proliferation) that
arise from therapies, can be challenging to detect during the early staging of treatment.
Clinical assessment of the progression of a primary brain tumour can be assessed by
contrast-enhanced MRI using one of the following criteria: Response Assessment in
Neuro-Oncology (RANO) criteria, Response Evaluation Criteria in Solid Tumours
(RECIST) or World Health Organization criteria.[5, 6] The RANO criteria, updated from
MacDonald criteria, includes measureable morphological changes in the tumour size due
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to therapy. Tumour response is divided into four different groups based on changes in
contrast-enhancing tumour volumes: 1. complete response with no tumour enhancement,
2. partial response with > 50% reduction in tumour size, 3. progressive disease with >
25% increase in tumour size, and 4. stable disease with no changes in tumour size. Other
criteria methods use similar categorizations of groups but differ in methodology for
measurement of tumour size. All criteria methods depend on the post contrastenhancement of tumours visualized using MRI. However, it is often difficult to determine
if the enhancement is a result of tumour reoccurrence, radiation necrosis or pseudoprogression.[5]
Tumour metabolism has been identified as a “hallmark of cancer”.[7] Tumours require an
increased amount of energy and nutrients to proliferate at a much faster rate compared to
healthy tissues. To sustain increased energy demands, tumour metabolism is altered.[8]
Most notably, energy production in tumour cells often switches from predominantly
oxidative phosphorylation in the mitochondria (Krebs cycle) to anaerobic glycolysis
(followed by lactic acid fermentation) in the cytosol.[9, 10] This is also known as
Warburg Effect. This choice of energy production generates an intracellular pool of lactic
acid as a potential molecular imaging biomarker.[11] Moreover, the excretion of lactic
acid and protons from tumour cells accelerates acidification of the extracellular space and
increases the viability of these cells through further vascularization.[10] Clinical studies
have demonstrated an increased metabolic uptake of 2-deoxy-2-[18F]fluoro-D-glucose
(18F-FDG) in tumours using positron emission tomography (PET).[12, 13] The ability to
monitor therapeutic changes accurately and in a timely manner in brain tumours will
provide a further understanding of tumour metabolism and guide initiation of alternative
(or salvage) therapies.
Hyperpolarized

13

C magnetic resonance spectroscopic imaging (13C MRSI) is an

emerging molecular imaging tool with MRI that can directly quantify metabolic changes
in tissues. A chosen cellular substrate is enriched with

13

(highly magnetized) in the polarizer to increase the potential

C and then hyperpolarized
13

C MRSI signal by nearly

five orders of magnitude.[14] After injection of the hyperpolarized

13

C-enriched

substrate, the substrate and its byproducts from metabolic processes can be individually
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detected in vivo by their inherent chemical shifts using magnetic resonance. The
hyperpolarized signal is transient as the magnetization of the 13C nuclei relaxes to thermal
equilibrium. This is highly dependent on the hyperpolarized contrast agent’s spin-lattice
relaxation time (T1) and that of its metabolic byproducts.[15]
The most common and widely researched hyperpolarized

13

C contrast agent is [1-

13

C]pyruvate.[16] After a bolus injection and circulation, hyperpolarized [1-13C]pyruvate

is taken up by cells through active transport,[17] and converted into three major
metabolic byproducts: [1-13C]alanine,

13

C bicarbonate and [1-13C]lactate.[16] Tumours

exhibit increased lactate production through upregulated lactate dehydrogenase (LDH)
production by oncogenes.[9] Cells targeted by metabolic therapy have reduced LDH
activity and thereby often exhibit reduced lactate production.[18, 19] The production of
[1-13C]lactate in tumour tissues by metabolizing injected hyperpolarized [1-13C]pyruvate
can be tracked using

13

C MRSI. In this way, the therapeutic response of tumours is

monitored by measuring changes in [1-13C]lactate conversion from [1-13C]pyruvate.
Both glioma and brain tissues are highly metabolic and readily uptake metabolites for
energy. This reduces the contrast and effectiveness of

18

F-FDG PET for imaging and

quantification of brain tumours which must be confirmed by other means.[13, 20, 21] For
instance, brain tissues express high background signal with 18F-FDG PET, particularly in
the cortex, due to high metabolic activity.[22] On the other hand, pyruvate is actively
taken up by glioma cells through monocarboxylate transport and rapidly converted to
lactate by upregulated LDH activity.[23, 24] Glioma cells are highly proliferative,
utilizing the lactate alternative energy source as well as amino acid production.[11] Thus,
MRSI of hyperpolarized [1-13C]pyruvate has an advantage of directly measuring
metabolic activity in glioma cells and the ability to distinguish these cells from other
highly metabolic brain tissues through their altered metabolic signature.
The purpose of this study was to monitor the metabolic response of tumours to chemoand radiotherapies using hyperpolarized 13C MRSI in an orthotropic rat model of glioma
and compare with conventional methods of treatment response assessment. Assessment
of tumour response to therapy using hyperpolarized 13C MRSI has been shown in several
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models and therapies;[25-29] however, no longitudinal study has compared therapeutic
responses to different therapies. Since each therapy relies on a different treatment
mechanism, this will likely produce different metabolic responses to treatment. As
discussed above, tumour response to therapy can be assessed by the observed ratio of [113

C]lactate with respect to [1-13C]pyruvate in the cytosol of tumour cells using 13C MRSI.

The results of this study illustrate the ability of

13

C MRSI of hyperpolarized [1-

13

C]pyruvate to quantify therapeutic response for different therapies and to follow tumour

progression or response with noninvasive longitudinal imaging.

3.2 Methods
3.2.1

Pyruvic acid sample preparation

A trityl radical, OX63 (Oxford Instruments, Concord MA, U.S.A.) was mixed with 99%enriched [1-13C]pyruvic acid (Sigma Aldrich, Miamisburg OH, U.S.A) to a final
concentration of 15mM. The pyruvic acid preparation was stirred and heated to 60°C to
dissolve, then cooled and stored at -4°C for later use. Before hyperpolarization, ProHance
gadolinium contrast agent (Bracco Diagnostics, Monroe Township, NJ, U.S.A.) was
added at a concentration of 1 mM to the pyruvic acid sample to enhance polarization and
reduce polarization time.[30]

3.2.2

Hyperpolarization

A Hypersense dynamic nuclear polarizer (Oxford Instruments, Abingdon, UK) was used
to hyperpolarize the prepared [1-13C]pyruvic acid sample. The DNP operates at a
temperature of 1.4 K and a magnetic field strength of 3.35 T. The pyruvic acid
preparation was irradiated with microwaves from a source operating at 94.125 GHz
achieving ~90% nuclear polarization of the solid after 45 min. For dissolution, the sample
was rapidly thawed and mixed with a super-heated 80-mM phosphate buffer solution
containing 0.34-mmol/L ethylenediaminetetraacetic acid. The resulting solution was
dispensed into a flask prior to uptake into a syringe for injection. The resulting 80-mM
hyperpolarized [1-13C] pyruvate buffered solution had a final volume of ~4 ml with a pH
of 7.4 at 37°C. Its measured T1 was ~ 65 s at 3 Tesla[15] and its liquid-state polarization
was > 12%.
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Figure 3-1 Hyperpolarized

13

C spectra of a rat brain with tumour. b) Regional spectral

data overlaid on T2-weighted image. Tumour has been outlined in cyan. a) & c)
Individual spectra from tumour and contralateral brain voxels. Red lines represent line
fitting to spectral data in yellow. Note the increased lactate signal relative to pyruvate
signal in the tumour voxel.

3.2.3

In Vivo Imaging

All imaging sessions were performed using a GE Discovery MR750 3.0 T MRI (General
Electric Healthcare, Waukesha WI, U.S.A.). A custom-built, switch-tuned
radiofrequency (RF) coil with a local
only/receive-only operating mode for

13
13

13

C-1H

C receive-only RF coil was used in transmit-

C imaging.[31] Switch-tuning between 1H and

13

C frequencies produced inherently registered images for morphology (1H) and

metabolism (13C). A single imaging session consisted of (in sequential order), T2weighted 1H imaging, hyperpolarized

13

C MRSI, and post-Gd contrast T1-weighted 1H

imaging. T2-weighted 1H images were acquired using a fast spin echo pulse sequence
with the following imaging parameters: 80  80 mm field of view (FOV), 0.3-mm
isotropic in-plane resolution, 3-mm slice thickness, repetition time (TR) = 4000 ms, echo
time (TE) = 85 ms, bandwidth = 10.42 Hz, echo train length = 16 and number of averages
= 4. For hyperpolarized 13C MRSI, animals were injected by tail vein with approximately
a 3-ml bolus of the buffered hyperpolarized [1-13C]pyruvate solution. 2D 13C-spectral
maps were acquired 25 s after the injection using free induction decay chemical shift
imaging (FID-CSI) with the following parameters: 60  60 mm FOV, 5-mm isotropic inplane resolution, slice thickness = 10 to 15 mm (depending on tumour extent), TR = 80
ms, spectral width = 5000 Hz and number of points = 256. Regional

13

C-spectra are
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shown in Figure 3-1. Prior to T1-weighted 1H imaging, 100 mM of Magnevist (Bayer
HealthCare Pharmaceuticals Inc., Whippany NJ, U.S.A.) was injected by tail vein
catheter. T1-weighted 1H images were acquired using a fast gradient echo pulse sequence
with the following parameters: 80  40  32 mm FOV, 0.5-mm isotropic resolution, flip
angle = 25°, TR = 6.9 ms, TE = 2.9 ms and 9 averages.

3.2.4

Animal disease model

Eighteen male Wistar rats (Charles River Laboratories, Senneville, QC, Canada) with an
initial weight of ~ 250 g (~ 5 to 7 weeks old) were used for this study. One million rat
glioma cells C6 (CCL-107, Purchased 2011, American Type Culture Collection,
Manassas, VA, U.S.A.) were stereotactically implanted in the caudate nucleus of the
right brain hemisphere (day 0). C6 cells were passaged 9 times and tested for
mycoplasma using MycoAlertTM (Lonza, Mississauga, ON, Canada) before use. Seven
days post cell implantation, animals underwent pre-therapy imaging sessions. On day 10,
animals were randomly divided into four groups: 1. no therapy, 2. radiotherapy, 3.
chemotherapy, and 4. radio- and chemotherapy (combined therapy). Group 1 (no therapy)
functioned as the control group. The radiotherapy group received a localized radiation
dose of 20 Gy in two fractions on two consecutive days to the tumour using a CT GE
Vision 120CT (General Electric Healthcare, Waukesha WI, U.S.A.) with a custom-built
collimator.[32] The chemotherapy group received intraperitoneal injections of 40 mg/kg
of TMZ (Sigma Aldrich, Miamisburg OH, U.S.A.) dissolved in dimethyl sulfoxide for 5
consecutive days. The combined therapy group received both therapies, with the same
timeline as described above. Starting on day 12, and every 3 days thereafter, animals
underwent post-therapy imaging sessions. At endpoint, rats were sacrificed for
histological examination. All animal procedures were approved by the University
Council on Animal Care, Animal Use Subcommittee.

3.2.5

Histology

Following the final post-therapy imaging session, the rats were injected by tail vein
catheter with 60-mg/kg Pimonidazole (Hypoxyprobe Inc., Burlington MA, U.S.A.) 30
minutes prior to sacrifice. The rats were then sacrificed, perfused with 4%
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paraformaldehyde (Sigma Aldrich, Miamisburg OH, U.S.A), and the brains were
extracted and refrigerated at 5 ºC in 4% paraformaldehyde. The brains were then
sectioned to 5-mm-thick paraffin slabs and later further sectioned to 5 μm for staining.
Brain sections were stained with hematoxylin & eosin (H&E) and for hypoxia. Wholebrain sectioned slices were scanned using light-fluorescent microscopy (Leica
Microsystems Inc., Concord ON, Canada). Histological image slices were co-registered
to the MRI images using Slicer (Version 4.31, Surgical Planning Laboratory, Brigham &
Women's Hospital Boston MA, U.S.A.) using a custom software plugin.[33]

3.2.6
The

13

Image analysis

C MRSI raw data were analyzed using a custom-written MATLAB (MathWorks,

Natick MA, U.S.A.) script. Free induction decay signals from each k-space point were
apodized by a 20-Hz Gaussian filter. The signals were spatially zero-filled and then
Fourier transformed in frequency and phase-encoding directions. Signal for the individual
metabolites is represented by the time-domain signal function as described in reference
[34]:
∗

𝑆(𝑡) = 𝐴𝑒 −𝑖𝛺𝑡+𝜙 𝑒 −𝑅2 𝑡 .

Equation 3-1

Here, S(t) is the signal at time t, A is the amplitude of the signal, Ω is the frequency
offset, and ϕ is the phase offset. 𝑅2∗ is the effective spin-spin relaxation rate given by
1

𝑅2∗ = 𝑇 ∗ . Each voxel could potentially contain up to 5 different summed metabolite
2

signals. Initial estimates for the parameters for each individual metabolite (Ai, Ωi, ϕi, and
∗
𝑅2𝑖
) were obtained by examining the data. The summed signal model for all observed

metabolites was fitted to the processed data by a nonlinear least-squares curve-fitting
method on a voxel-by-voxel basis to extract metabolite parameters and their
uncertainties. These parameters were used to calculate the lactate to pyruvate ratio
(Lac/Pyr ratio) and propagate an associated uncertainty. An example of spectral fitting is
showing in Figure 3-1.
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3.2.7

Statistics

Post-Gd tumour volumes were measured from the T1-weighted contrast images using
ITK-Snap (www.itksnap.org, [35]). Boundaries of tumours were manually contoured and
the volumes were calculated. Inter-observer variability was used for the error of tumour
volume. Cohort statistics were calculated using SPSS (IBM Corp., Armonk, NY USA).
Analysis of variance (ANOVA) with Dunnett's post hoc test was performed to calculate
the statistical differences between groups at each day and overall group differences
respectively. The uncertainties propagated from parameter fitting were used to weight
Lac/Pyr ratios for ANOVA analysis. Uncertainties for the Lac/Pyr ratio are reported as
standard error of the mean of measurements. The correlations between Lac/Pyr ratio,
tumour volume and tumour growth rate were tested using Pearson correlation.
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3.3 Results

Figure 3-2 Kaplan-Meier survival plot. Tumour implantation surgery was on Day 0 and
the experimental endpoint was Day 24. Therapies were initiated on Day 10, lasting 2 days
for radiotherapy and 5 days for chemotherapy. Specific details regarding the therapies are
included in the text.
A total of 18 rodents were monitored using hyperpolarized [1-13C]pyruvate MRSI at
multiple time points: 7, 12, 15, 18, 21 and 24 days after tumour implantation. During the
course of the longitudinal study, the health of some animals deteriorated due to the
increased tumour burden and these animals were sacrificed earlier than the expected
endpoint. Figure 3-2 depicts the survival rate of each group. The radio- and combined
therapy groups had the highest mean survival time at 25 days followed by chemotherapy
at 18 days and lastly the no therapy group at 17 days. A Kaplan-Meier method was used
to determine if there were any differences in the survival distribution for the therapy
groups. The survival distributions for different therapy groups are statistically different (p
< 0.0005).

57

Figure 3-3 A single representative animal from the no therapy group. a) Lactate-toPyruvate ratio maps are overlaid on axial proton images of the rat brain at longitudinal
imaging time points. Tumours are outlined by cyan boundaries. b) Bar graph of measured
lactate-to-pyruvate ratio of tumours and contralateral brain volumes at different imaging
sessions. c) Graph of tumour volume for all imaging time points. The error bars for
Lac/Pyr data represent one measurement standard deviation. The uncertainty for the
tumour volume was estimated from inter-observer measurement variability.
Figures 3-3 and 3-4 illustrate longitudinal assessments of therapeutic response in a rat
model of glioma comparing Lac/Pyr ratio and tumour volume Figure 3-3 shows
longitudinal imaging data for a representative rodent from the no-therapy group. Rapid
tumour growth is readily apparent in Figure 3-3 a) and is quantified in 3-3 c).
Longitudinal measurements of the Lac/Pyr ratio are presented in Figure 3-3 b),
comparing tumour and contralateral brain for each

13

C imaging session. Higher Lac/Pyr

ratios are observed in tumour tissue compared to contralateral brain tissue. Lac/Pyr ratio
increased with tumour growth. As illustrated in Figure 3-3 c), without any therapy, the
tumour grew rapidly. Due to the large tumour burden and resulting adverse health effects,
the rodent was sacrificed before the last imaging session at day 24, in compliance with
terms of the animal use protocol. Neurological impairment and lack of appetite were
observed for all rodents that did not receive therapy and as a result, these animals were
sacrificed before the final imaging time point, typically between days 15 and 21.

58

Figure 3-4 Representative animal from the combined therapy group. a) Lactate-toPyruvate ratio maps are overlaid on axial proton images of the rat brain at longitudinal
imaging time points. Tumours are outlined by cyan boundaries. b) Bar graph of measured
lactate-to-pyruvate ratio of tumours and contralateral brain volumes at different imaging
sessions. Treatment periods are indicated as hatched areas. c) Graph of tumour volume
for all imaging time points. The error bars for Lac/Pyr data represent one measurement
standard deviation. The uncertainty for the tumour volume was estimated from interobserver measurement variability.
Figure 3-4 shows a representative rodent from the combined therapy group. Tumour
growth shown in Figure 3-4 a) and quantified in 3-4 c) is slower compared to that of the
no therapy group. On day 7, the Lac/Pyr ratio is higher in the tumour than in contralateral
brain tissue (see Figure 3-4 b)). Within two days post therapy, the tumour Lac/Pyr ratio
drops to that of contralateral brain. Further longitudinal measurements show similar
Lac/Pyr ratios in tumour and healthy brain until the final imaging session on day 24.
Reduced tumour growth assessed by volume measurements commensurate with
therapeutic response was not apparent until day 21.
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Figure 3-5 Longitudinal assessment of the lactate-to-pyruvate ratio in tumour tissue for
four therapy groups. Radio- and chemotherapy were initiated on day 10 for a duration of
2 and 5 days respectively. No statistical comparison between the no therapy and other
treatment groups was possible for days 21 and 24 due to the poor survival of the
untreated group. (Details of therapy are in the text.) Error bars represent one standard
deviation for the averaged animal data.
Figure 3-5 illustrates a longitudinal comparison of the average Lac/Pyr ratio in tumours
for the four therapy groups measured up to 24 days post cell implantation. A consistently
elevated Lac/Pyr ratio was observed in the tumours for the no therapy group for all time
points. No statistical comparison between the no therapy and other treatment groups was
possible for days 21 and 24 due to the poor survival of the untreated group. Some of the
rodents that received radiotherapy showed a Lac/Pyr ratio reduction in the tumour tissue
at day 12, but as a whole, that group did not show a significant reduction (p  0.33). The
rodents that received either chemotherapy or combined therapy show a statistically
significant reduction in the Lac/Pyr ratio within the tumour volumes (p < 0.05) posttherapy (Day 12, 15 and 18). However, the rodents that received only chemotherapy did
not survive to the endpoint at day 24 despite a significant reduction in the Lac/Pyr ratio.
Application of combined therapy produced the best therapeutic response as assessed by
tumour Lac/Pyr ratio and confirmed by the survival data.
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Tumour volume measured from T1-weighted post-Gd images at day 18 show similar
trends as Lac/Pyr ratio. In the absence of therapy, tumour volumes significantly increased
in size until animals were sacrificed. The average enhancing tumour volume in the no
therapy group at endpoint was 384 ± 63 mm3. All applied therapies showed reduced
tumour growth by endpoint assessed by volume measurement. The average enhancing
tumour volume for chemotherapy, radiotherapy and combined therapies were: 140 ± 23,
107 ± 18 and 54 ± 9 mm3 respectively at endpoint. Rodents with tumours that received
radiotherapy and combined therapy would be classified as having stable disease based on
the RANO criteria. Whereas, for rodents with tumours that received chemotherapy, the
observed tumour volume growth rate would produce a classification of progressive
disease. Notably, when using only the T1-weighted post-Gd images as one would in the
clinic, these classifications would only be possible as early as 18 days after cell
implantation.

Figure 3-6 Comparison of T2-weighted images, lactate-to-pyruvate ratio maps, H&E
staining and hypoxia staining for a representative no-therapy and combined therapy
animal. A non-rigid image registration method has been used to co-register the histology
to the MRI data. Magnified regions for H&E and hypoxia staining are presented next to
the histology for the entire brain. Hypoxia staining (Pimonidazole) shows green contrast
with blue nucleus counter staining.
Figure 3-6 presents the representative histological results comparing rodents that received
either no therapy or combined therapy. The T2-weighted image, Lac/Pyr ratio images, and
histological sections have been co-registered as described above. The tumours within the
brain are easily distinguishable by 1H MRI and H&E staining. Lac/Pyr ratio and hypoxia
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staining show similar contrast between tumour and contralateral brain tissues. Comparing
contralateral brain and tumour measurements, rodents that did not receive therapy
showed higher Lac/Pyr ratio activity and hypoxia within the tumour, whereas animals
that received combined therapy had minimal Lac/Pyr ratio activity through the entire
brain and no hypoxia signal within the tumour at endpoint.

Figure 3-7 Correlation plots for all experimental animal groups. a) Correlation plot of
lactate to pyruvate ratio in tumour versus tumour volume b) Correlation plot of lactate to
pyruvate ratio in tumour versus tumour growth rate. The Pearson correlation coefficients
are 0.287 (p ~0.105) and 0.66 (p <0.001) and R2-values are 0.083 and 0.416 for panels a)
and b) respectively. Tumour volumes (in mm3) were estimated at each imaging time point
from T1-weighted images acquired after contrast enhancement. An exponential growth
model was fit to the tumour volume data to estimate tumour growth rate in mm3/day.
Tumour volumes were contoured and measured using post-Gd contrast enhanced T1weighted images acquired at each imaging time point. Tumour growth rates were
modeled from these measurements. The correlations of tumour Lac/Pyr ratio versus
tumour volume and growth rate are presented in Figure 3-7. The Pearson correlation
coefficients for these data are 0.287 (p ~ 0.105) and 0.66 (p < 0.001) respectively.
Tumour Lac/Pyr ratio was not correlated with tumour volume; however, a moderate and
statistically significant correlation with tumour growth rate was observed.
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3.4 Discussion
The goal of this study was to demonstrate the ability to detect early changes in
therapeutic response in tumours using hyperpolarized [1-13C]pyruvate MRSI and to
evaluate potential clinical translation. Targeted therapy of tumour metabolism has gained
more interest recently but therapeutic effects on tumour metabolism are not fully
understood.[36] The ability to measure metabolic changes in tumours will aid to not only
further understand tumour metabolism, but may also provide biomarkers to determine
which therapeutic methods will be effective against tumours.
The C6 rodent glioma model was chosen to study the therapeutic response of solid
tumours because this model is well established in the literature and its tumour
characteristics are well defined.[37, 38] During glioma progression, the tumour evolves
into two different regions. The outer layer of tumour is highly vascularized and wellperfused, whereas the inner core of the tumour becomes necrotic and hypoxic due to lack
of functioning or effective vasculature.[39] In addition, as the tumour grows, the blood
brain barrier becomes disrupted, which can allow for increased fluid exchange with the
vasculature.[40] In MRI, tumours, edema, and cerebrospinal fluid appear hyperintense on
T2-weighted 1H images,[41] complicating tumour volume measurements. Therefore, T1weighted post-Gd 1H images were used to measure tumour volumes. Given that
malignant glioma possesses disrupted and leaky vasculature, low-molecular weight
paramagnetic contrast agents can effectively accumulate within the tumour.[42] Post-Gdcontrast T1-weighted 1H images were used to determine tumour volumes in this study.
Contrast-enhanced tumours have increased conspicuity with hyperintense contrast
compared to surrounding brain tissue for T1-weighted 1H images. In addition, regions of
edema and necrosis can be discriminated by lack of enhancement.[43]
Figures 3-3 and 3-4 show the progression of glioma in two different therapy groups using
tumour volumes measured from T1-weighted 1H images. C6 glioma cells are extremely
aggressive and grow exponentially as shown Figures 3-3a) & c). The RECIST criteria are
the conventional indicators of therapeutic response. Post-therapy success is associated
with stability or recession of tumour size. To detect post-therapeutic changes, tumour
volume must be monitored repeatedly after therapy. In this model, using the standard
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clinical method of detection with 1H imaging, the earliest post-therapeutic tumour volume
changes were observed on day 18 (8 days after the therapy was given) and later
confirmed to be stable disease. Tumour recurrence was not observable in this study due
to the finite length of the study. Prolonged monitoring of post-therapeutic tumour volume
changes would be required to dismiss tumour recurrence. Considering that most
malignant gliomas eventually recur despite rigorous therapies,[1] early detection of
therapeutic response or progression would not only be essential for prediction of
prognosis but also improve quality of life for patients by terminating treatment when it is
not effective.
The purpose of this study was to evaluate the effectiveness of hyperpolarized 13C MRSI
to detect early therapeutic changes by measuring tumour metabolism. Metabolic changes
such as upregulated glucose uptake in tumours are clinically assessed by

18

F-FDG PET.

However, 18F-FDG is also readily taken up by highly metabolic tissue. This leads to the
possibility of false positive results for 18F-FDG PET, which may require confirmation by
other means.[13, 20, 21] For example, high metabolic activity in the cortex of the brain
can produce an elevated background signal, which confounds the interpretation of

18

F-

FDG PET results.[22] As an alternative, radiolabeled amino acids can be used to target
brain tumours because amino acids are essential to highly proliferating tissues.[22, 44]
Hyperpolarized

13

C-labeled glucose can be used in a similar manner as

18

F-FDG for

tumour detection and characterization; however significant challenges exist. First, the T1
of hyperpolarized

13

C labeled glucose is too short (< 2 s) for detection of metabolic

byproducts.[45] The T1 of glucose can be substantially increased by replacing all protons
in the glucose with deuterium but this significantly increases the cost of this
substrate.[46] Secondly, the labeling of various carbon atoms in the glucose molecule
results in different chemical shifts for its 13C nuclei and those of its metabolic byproducts.
Often these chemical shifts are close to each other, which complicates the separation of
metabolites as the spectrum becomes congested. In this study, we used [1-13C]pyruvate as
the metabolic probe agent, which offers several advantages over glucose. The T1 of [113

C]pyruvate at 3 T is ~ 65 s in vitro (~ 45 s in vivo), which is long enough for pyruvate

to circulate through the circulatory system of our animal model and converted to
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downstream metabolites.[15] Furthermore, the 13C-labeled carbon can only be transferred
to four different metabolites; lactate, pyruvate hydrate, alanine, and bicarbonate. All these
metabolites are individually represented as single spectral peaks and are well separated
by their chemical shifts producing a fully resolved spectrum, which can be readily
quantified as shown in Figure 3-1.
Among the metabolites produced from [1-13C]pyruvate, the [1-13C]lactate signal is a
sensitive biomarker for therapeutic effect in tumours where its production from pyruvate
can be correlated with LDH activity and lactate pool (cellular redox state). The [113

C]lactate signal is normalized to the [1-13C]pyruvate signal to mitigate differences in

pyruvate delivery and uptake in tumours and compared with that of healthy brain tissue.
Increased LDH activity in metabolically active tumour cells will result in an increase in
observed Lac/Pyr ratio, whereas necrotic tumour regions or healthy cells will have little
to no lactate production as a result of limited LDH activity and a lower Lac/Pyr ratio. As
illustrated in the representative case for a rodent that received no therapy in Figure 3-3 b),
the Lac/Pyr ratio in tumour tissue is consistently larger than that of the healthy
contralateral brain tissue. Furthermore, increased Lac/Pyr ratio corresponds to rapid
progression of the tumour as shown in Figure 3-3 c). This is further demonstrated in the
correlation plots of Figure 3-7. Here, tumour volume does not statistically correlate with
Lac/Pyr ratio. Yet, there was a moderate and statistically significant correlation between
Lac/Pyr ratio and tumour growth rate. Thus, Lac/Pyr ratio is potentially related to the
growth of tumour which coincides with increased LDH activity rather than tumour
volume.[47] This suggests that in principle, measurement of Lac/Pyr ratio at a single time
point can be predictive of tumour response, which would require longitudinal tumour
volume measurements over time for conventional assessment.
As tumours rapidly grow, ineffective vascularization and necrosis of the core becomes
evident. In Figure 3-3 a), particularly on day 21, there was inadequate delivery of
hyperpolarized [1-13C] pyruvate to regions of the tumour precluding sufficient metabolite
signal for accurate quantification of the Lac/Pyr ratio. For representative animals, blood
volume and flow were longitudinally measured using dynamic susceptibility contrast
imaging (data not shown). The blood flow and blood volume in tumour were lower than
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contralateral brain and this may indicate decreased tumour perfusion and possibly
necrosis at that time point.
Conversely, as illustrated in the representative case for the rodent that received combined
therapy (Figure 3-4 b)), two days after starting the combined therapies, the tumour
already exhibited a reduced Lac/Pyr ratio compared to day 7. This ratio was comparable
to that of the remaining brain tissue over the rest of the longitudinal experiment. Changes
in Lac/Pyr ratio in tumour tissue directly suggests a reduction in LDH activity and cell
death and potentially effective therapeutic response. Measured Lac/Pyr ratios in both
tumour and contralateral brain declined and remained low after the window of therapy.
This might be a result of inflammation, which subsided after treatment caused by
radiotherapy, intracranial hypertension from the growing tumour and/or a side-effect of
the administration of chemotherapy.[48] For this representative animal, blood flow and
blood volume in the tumour and contralateral brain were also measured. The blood flow
and blood volume in tumour were returned to a level consistent with the contralateral
brain region approximately 14 days after therapy. (data not shown) The restoration of
blood flow and blood volume suggests changes in tumour vasculature due to therapy.
However, this observation can be only made in the later time points of the experiment.
The large variation in blood flow and blood volume is a result of differences between the
boundary of the tumour compared to the core of tumour.[49] The boundary of the tumour
shows increased blood flow and blood volume compared to the core when it is treated.
This leads to a reduction in therapeutic efficacy near the tumour core where there is
limited blood flow and blood volume.
In the clinic, patients diagnosed with glioma undergo surgery followed by radio- and
chemotherapy.[50] Unfortunately, the effectiveness of a particular therapeutic method for
an individual patient may be unclear because of variation in tumour progression among
patients. Determining the efficacy of therapy as early as possible would provide an
important tool for evaluation of new therapies and improved survival to patients. Figure
3-5 shows the average Lac/Pyr ratio in tumours for the no therapy group and three
therapy groups. As expected, the no therapy group shows elevated Lac/Pyr ratio sustained
throughout the study, which is possibly due to increased tumour LDH activity. Blood
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flow and blood volume ratios suggests that the tumour was poorly vascularized and
necrotic; however, these data were not collected for all animals and, as a result, no
absolute conclusion can be drawn.
Among the three therapy groups (radiotherapy, chemotherapy, and combined therapy),
the combined therapy group had the highest survivability and displayed significant
reduction in Lac/Pyr ratio within the tumours. Combined therapy is expected to induce
greater DNA damage compared to a single therapy alone, which leads to cellular
apoptosis, reduced LDH activity and tumour burden.[51] In the literature, significant
evidence exists suggesting radiotherapy helps to increase vasculature permeability and
improve delivery of chemotherapeutic drugs to tumour sites.[52, 53] The chemotherapy
group showed a statistically significant reduction of Lac/Pyr ratio in tumours; however,
this group of rats had a high rate of mortality. Chemotherapy animals lost a significant
amount of weight after therapy despite a moderate dose of TMZ given to those rats.[54,
55] TMZ is known to cause nausea, vomiting, fatigue, headache as adverse reactions in
human.[55, 56] These side effects, may have been the cause of weight loss for these
animals, which negatively impacted their survivability. This may suggest that
chemotherapy on its own is sufficient to cause dysfunction in tumour metabolism and
proliferation; however, it is not potent enough alone to extend survival. The radiotherapy
group has a slow and not statistically significant decline in the Lac/Pyr ratio, yet this
group had low mortality compared to the chemotherapy group. In fact, there was a large
variation in the Lac/Pyr ratio after therapy among the radiotherapy group suggesting the
radiotherapy efficacy varies among the cohort. Despite injecting approximately the same
number of C6 cells and providing a standard conformal radiation dose, an individual
animal can show a varied therapeutic response to radiotherapy. Those tumours that did
not response to radiotherapy may indicate resistance to therapy and tumour recurrence.
However, the experimental timeline would need to be extended to confirm the metabolic
profile associated with resistance to therapy and recurrence.
Lastly, Figure 3-6 presents histological validation of Lac/Pyr measurements in the tumour
model. Histological sections have been co-registered to the MR imaging data for accurate
comparison. Tumour location and size are apparent from H&E images and with 1H MRI.
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Although the T2-weighted contrast would suggest that the tumours are relatively
homogenous, at least in structure, it is apparent from the Lac/Pyr ratio map and hypoxia
staining that tumour metabolism varies throughout the tumour. The untreated tumour
shows strong hypoxia staining as well as a high Lac/Pyr ratio. As previously noted in the
literature, the tumour environment becomes hypoxic leading to increasing LDH activity.
However, following effective therapy, the large reduction in the Lac/Pyr ratio shown in
the combined therapy group compared to the no therapy group suggest a reduction in
LDH activity. This is further verified by differences in the hypoxia staining between
these two cohorts. For the untreated tumour, increased LDH activity is associated with a
hypoxic tumour environment due to insufficient or inefficient vascularization, which was
verified by hypoxia staining at endpoint. For the combined therapy group, reduced
hypoxia was observed commensurate with the lower measured Lac/Pyr ratios. Looking
forward to clinical translation, these findings suggest that the Lac/Pyr ratio is a noninvasive imaging biomarker for assessment of hypoxia in the tumour microenvironment,
which may be a useful tool for early assessment of tumour response to therapy.
In summary, this study examined longitudinal therapeutic response to different therapies
using hyperpolarized [1-13C]pyruvate MRSI. For cases where a standard treatment is
ineffective, early assessment of therapeutic response is highly desirable to prompt
alternative or salvage therapies or to improve end-of-life care. We have observed
different early therapeutic responses assessed by changes in the Lac/Pyr ratio of tumour.
All therapies produced unique changes in the Lac/Pyr ratio compared to the no-therapy
control group. In contrast, therapeutic assessment using tumour volume showed a similar
time-course to that assessed by Lac/Pyr ratio; yet, significant changes were not
discernable until much later after therapy. Heterogeneous response to therapies observed
in individual animals and across therapy groups was well characterized by hyperpolarized
[1-13C]pyruvate MRSI. Lac/Pyr ratio measured across therapy groups was demonstrated
to be correlated with tumour growth after initiation of therapy. Regional differences in
Lac/Pyr ratio were compared with histology at endpoint and have been shown to be
consistent with hypoxia. In conclusion, this study demonstrates the use of hyperpolarized
[1-13C]pyruvate to probe real time tumour metabolism, which can provide a useful
longitudinal non-invasive biomarker for assessment of therapeutic response.
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Longitudinal Measurement of Intra- and Extracellular
pH gradient in a Rat Model of Glioma

Heeseung Lim, Mohammed Albatany, Francisco Martínez-Santiesteban, Robert Bartha
and Timothy J. Scholl
An updated version of the following chapter will be submitted to Tomography as a
journal manuscript.

4.1 Introduction
Cancer is a physiologically and genetically diverse disease resulting in abnormal cellular
proliferation. Cancer cells have altered biological pathways and microenvironment that
support this proliferation. These changes have been widely studied and some categorized
as hallmark features of cancer because they are common to many types of genetically
diverse tumours.[1] These hallmark features impact on important aspects of cancer
progression and therapy. Among the identified hallmarks, the deregulation of metabolism
and poor vascularization are main contributors to altered intra- and extracellular pH
within tumours.[1-4] Altered tumour pH, in particular the intracellular to extracellular pH
gradient, is an important factor that drives cancer progression, by enhancing oncogene
expression, increasing metastatic potential, and altering drug efficacy.[5, 6]
The cellular pH gradient is defined as the difference between intracellular pH (pHi) and
extracellular pH (pHe). In normal tissue, pHi is ~7.2 and pHe is ~7.4,[7-9] resulting in a
negative pH gradient (~ -0.2) across the cellular membrane. In contrast, tumour cells
possess a positive pH gradient (~ 0.5), where pHi is ~7.4 and pHe is ~6.9.[7, 8, 10-12]
This reversal of the pH gradient is the result of modified cellular metabolism, which
promotes tumour cell growth and invasion. As most tumour cells favor anaerobic
metabolism over aerobic metabolism, even with the presence of oxygen (Warburg effect),
the rate of glycolysis and lactic acid production is increased.[4] Significant decreases in
intracellular pH due to accumulation of metabolic acids, would normally damage a cell,
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but tumour cells actively maintain homeostasis by transporting protons into the
extracellular space.[13] Inefficient tumour vasculature is not able to completely support
the bicarbonate/carbon dioxide buffer system so that the extracellular space of tumour
becomes more acidic.[13] This leads to destruction of the extracellular matrix, promoting
tumour cell invasion and eventually metastasis.[7] The tumour pH gradient is further
increased as the tumour becomes hypoxic and the vasculature fails to provide sufficient
buffers. [14] Non-invasive measurement of the tumour pH gradient would aid in
treatment planning and evaluating treatment response.
Several non-invasive imaging techniques have been developed to quantify intra- and
extracellular tissue pH.[10] In this study, intracellular tissue pH was measured using a
novel chemical exchange saturation transfer (CEST) magnetic resonance imaging (MRI)
technique called amine and amide concentration-independent detection (AACID).[15]
This method exploits the differential pH dependence of the exchange rate of amine and
amide protons with bulk water to measure pH. A CEST image is produced to determine
the ratio of the amine to amine CEST effect, which can be converted into a measurement
of intracellular pH from a separate calibration.[15] Extracellular tissue pH was measured
with hyperpolarized

13

C magnetic resonance spectroscopic imaging (MRSI). The use of

13

C-labelled bicarbonate as a contrast agent to evaluate pHe was previously reported in

the literature.[16] Hyperpolarized

13

C bicarbonate is injected into the vasculature and

after circulation reaches the tissue of interest where it exchanges with the pre-existing
bicarbonate/carbon dioxide pool under carbonic anhydrase activity. Extracellular pH can
be derived from the Henderson-Hasselbalch equation using the ratio of
and

13

CO2 measured by

13

13

C bicarbonate

C MRSI. By serially combining these approaches, the pH

gradient of tissue can be mapped and quantified in the same pre-clinical model.
This study followed the progression of the pH gradient of tumour cells in an untreated
orthotopic rodent model of glioma. C6 rat glioma tumours exhibit rapid growth,
vascularization and invasion.[17] Previous studies have noted that these tumours develop
necrotic cores and exhibit regional hypoxia.[17, 18] Adequate vascularization facilitates
effective delivery of hyperpolarized

13

C bicarbonate to the tumour. For this aggressive
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tumour model, significant changes in the pH gradient are expected over time, making it
an ideal solid tumour model for longitudinal studies of tumour pH.
The purpose of the study was to measure and characterize longitudinal changes in the
tumour pH gradient. There have been several studies measuring pH of tissue using
techniques as described above.[15, 16, 19-21] However, no longitudinal study exists
measuring both pHe and pHi in a consecutive fashion to map regional differences and
temporal changes in pH gradient in an untreated tumour. We hypothesized that the pH
gradient would increase over time as the tumour increased in size. Knowledge of pH
gradient is vital for tumour characterization and selecting appropriate therapy, since the
outcome of therapy can be dependent on pH. The results of this study provide insight
regarding changes in tumour pH linked to aggressive growth.

4.2 Methods
4.2.1

13

C Bicarbonate Sample Preparation

95% enriched

13

C cesium bicarbonate (Sigma Aldrich, Miamisburg OH, U.S.A.) was

dissolved in a 4:1 glycerol and deuterium oxide mixture at a final concentration of 6.3
mol/L. In addition, OX63 trityl radical (Oxford Instruments, Concord MA, U.S.A.) and
ProHance gadolinium contrast agent (Bracco Diagnostics, Monroe Township, NJ,
U.S.A.) were added to the sample at final concentrations of 25 mmol/L and 0.5 mol/L
respectively. The final mixture was heated to 60°C and stirred to dissolve. The resulting
bicarbonate preparation was stored at -4°C for later use.

4.2.2

Hyperpolarization

13

C cesium bicarbonate was hyperpolarized using dynamic nuclear polarization (DNP)

(HyperSense, Oxford Instruments, Abingdon, UK). The bicarbonate sample was cooled
to 1.4 K at 3.3 T in the DNP apparatus and irradiated with 50 mW of microwave
radiation at a frequency of 94.123 GHz to transfer electronic spin magnetization to the
13

C-labelled bicarbonate. Approximately 90% solid state polarization was achieved

during two hours of hyperpolarization. The sample was rapidly mixed with a superheated mixture of 80-mmol/L phosphate buffer (pH = 7.2) and 100-mg/L
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ethylenediamine tetra-acetic acid disodium salt dehydrate (EDTA, Sigma-Aldrich, St.
Louis MO, U.S.A.). The resulting hyperpolarized solution had a

13

C bicarbonate

concentration of 150 mmol/L and a pH of 7.4 at 37°C. The in vitro spin lattice relaxation
time and polarization values of the 13C nucleus were 26.2  1.4 s and ~7.5% measured at
3 T.[22]

Figure 4-1 Calibration data for different pH-buffered solutions mixed with
hyperpolarized

13

C bicarbonate. a) A pH map derived from

13

C MRSI and the

corresponding pH values obtained by pH meter. b) The linear regression between
measured pH (pH meter) and observed pH (hyperpolarized 13C bicarbonate) with R2 = 1.

4.2.3

Phantom Imaging

To calibrate pH measurement from hyperpolarized

13

C bicarbonate, four separate

phosphate buffers with different pH values (6.4, 6.6, 6.8, 7.0) were prepared prior to the
experiments. One milliliter of each phosphate buffer was mixed with an equal volume of
200 mmol/L buffered hyperpolarized

13

C bicarbonate solution. For catalysis, 1 mg of

carbonic anhydrase (Sigma Aldrich, Miamisburg OH, U.S.A.) corresponding to ~2500
Wilbur-Anderson units, was added to each solution as a catalyst. The resulting mixtures
were imaged with MRSI at 3 T (General Electric Healthcare Discovery MR750 3.0 T,
Milwaukee WI, U.S.A.). Immediately after imaging, the pH of each mixture was
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recorded using a pH meter (VWR Symphony SB70P digital bench-model pH meter,
VWR International, Mississauga ON, Canada)

4.2.4

Animal Model

A total of 7 Wistar rats weighing approximately 250 g (~5 to 7 weeks old), were used in
this study. On day zero, animals were surgically implanted with approximately one
million C6 rat glioma cells in the right caudate nucleus of the brain. Animals were
scanned on days 8, 12 and 15. CEST was performed first using a 9.4 T small animal MRI
scanner (Agilent, Santa Clara, CA) to measure pHi. Under anesthesia, the animals were
then transferred to the same 3 T MRI for hyperpolarized 13C MRSI to determine pHe. All
animal procedures were performed in accordance with relevant guidelines and regulations
stipulated by an animal use protocol approved by the University Council on Animal Care,
Animal Use Subcommittee at Western University.

4.2.5

Chemical Exchange Shift Imaging for Intracellular pH

CEST imaging on the 9.4T MRI was performed with a 50-mm-diameter volume birdcage
coil built in-house. Standard anatomical T2-weighted images were used for tumour
localization. The T2-weighted images were acquired using a 2D fast spin-echo pulse
sequence (FSE) with the following parameters: field of view (FOV) = 38.4  38.4 mm,
0.3-mm isotropic in-plane resolution, slice thickness = 1 mm, repetition time (TR) = 3000
ms, echo time (TE) = 10 ms, echo train length (ETL) = 4, and effective TE = 40 ms.
Upon initial tumour detection by MRI, two slices from the T2-weighted image data with
maximum tumour extent were selected for CEST imaging. Three sequential CEST
images were acquired using an FSE sequence with the following parameters: FOV = 38.4
 38.4 mm, 0.6-mm in-plane resolution, slice thickness = 2 mm, TR = 7000 ms, TE = 7
ms, ETL = 32, effective TE = 7 ms and preceded by a continuous RF pulse with an
amplitude of 1.5 µT and duration of 4s. CEST images were acquired at different
saturation frequencies (1.2 to 4.5 (∆=0.1) ppm, from 5.4 to 6.6 (∆=0.1) ppm, -1000 and
1000 ppm images were acquired as reference, producing a total of 49 images). For B0
correction, a water saturation shift referencing (WASSR) technique was used.[23] A
linearly spaced 37-point WASSR CEST spectrum with saturation frequencies from -0.6
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to 0.6 ppm was acquired using the same pulse sequence except preceded by a shorter
duration RF saturation pulse (100 ms) with low amplitude (0.2 µT). Each WASSR
spectrum and CEST spectrum was interpolated to achieve 1-Hz resolution. Each CEST
spectrum was then frequency shifted, using the corresponding WASSR spectrum, to
account for B0 variation. B0 variations were corrected on a pixel-by-pixel basis. The three
CEST spectra were summed for each pixel following B0 corrections to increase signal to
noise ratio. A B1 field map was generated using a flip-angle imaging (FAI) pulse
sequence (TR = 20 ms, TE = 3.47 ms, echoes = 2, flip-angle = 700, FOV = 38.4  38.4
mm2, matrix size= 64  64). Observed B1 variations in the CEST slice were less than 5%,
and no B1 correction was applied.

4.2.6

Hyperpolarized 13C Bicarbonate MRSI for Extracellular pH

A switch-tuned 1H images and

13

13

C RF coil was used to acquire inherently co-registered proton

C MRSI data of the rat models.[24] Tumours were identified using a T2-

weighted anatomical 1H scan of the rat brain using a FSE sequence with the following
parameters: 80.0  80.0 mm FOV, 0.3-mm isotropic in-plane resolution, 3-mm slice
thickness, TR = 4000 ms, TE = 85 ms, bandwidth = 10.42 kHz, ETL = 16, and number of
averages = 4. Prior to hyperpolarized

13

C imaging, rats were injected with 3 ml of

buffered hyperpolarized 13C bicarbonate solution in a single twelve-second bolus through
a tail vain catheter. Dynamic 13C maps of bicarbonate and carbon dioxide were collected
using a spectral-spatial excitation chemical shift imaging sequence (FIDALL[25]) with
the following parameters: two frequency excitations (bicarbonate and CO2, 35.5 ppm
difference), 60.0  60.0 mm FOV, 3.5 mm isotropic in-plane resolution, slice thickness
~12 mm, TR = 350 ms, and 5°/90° flip angle for bicarbonate/CO2 excitation.

4.2.7

Data analysis

Data analysis of the CEST and hyperpolarized

13

C bicarbonate MRSI was performed

using MATLAB (Mathworks, Natick, MA, USA). Using B0-corrected and smoothed
CEST spectra, AACID values were measured on a voxel-by-voxel basis. AACID data
represent the ratio of the CEST effects of amine protons resonating at 2.75 ppm and
amide protons at 3.50 ppm, normalized by magnetization transfer effects measured after
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saturation at 6.0 ppm and are calculated using the following equation from McVicar et.
al.:[15]
𝑀 (3.50 𝑝𝑝𝑚)×(𝑀 (6.00 𝑝𝑝𝑚)−𝑀 (2.75 𝑝𝑝𝑚))

AACID = 𝑀𝑧 (2.75 𝑝𝑝𝑚)×(𝑀𝑧 (6.00 𝑝𝑝𝑚)−𝑀𝑧 (3.50 𝑝𝑝𝑚)).
𝑧

𝑧

Equation 4-1

𝑧

Here, Mz(f) is the magnitude of the CEST signal at a specific frequency, f. AACID is
linearly-dependent on pHi and is insensitive to change in T1 relaxation time, temperature,
and macromolecule concentration.[15] We calibrated the relationship between AACID
and pH in both tumour and contralateral brain ROIs. For hyperpolarized 13C bicarbonate
MRSI, non-Cartesian k-space data were reconstructed into maps of

13

C-bicarbonate and

13

C-carbon dioxide.[26] Regional pH was calculated using the Henderson-Hasselbalch

equation: [27]
pH𝑒 = p𝑘𝑎 + log10

[𝐻𝐶𝑂3− ]
[𝐶𝑂2 ]

Equation 4-2

Here, pHe is the extracellular pH, pka (6.17)[27] is the base-10 logarithm of the acid
dissociation constant of carbonic acid and [HCO3-] and [CO2] are the concentrations of
bicarbonate and carbon dioxide respectively. The concentration ratio of bicarbonate to
carbon dioxide is determined as the ratio of MRSI signal amplitudes of

13

C-bicarbonate

and 13C-carbon dioxide after corrections for individual flip angle excitations.

4.2.8

Statistics

The region of interest (ROI) for tumour and contralateral brain tissues were manually
segmented on both 3T and 9.4T T2-weighted images using ITK-Snap (www.itksnap.org,
[28]) prior to any image registration. From ROIs, tumour volumes were measured and
inter-observer variability was used for the volume error. For each animal and time point,
the mean and standard deviation for pHi and pHe were calculated from these ROIs (SPSS,
IBM Corp., Armonk, NY USA). All pH errors represent one standard deviation of the
weighted mean value. The statistical significant across pHi & pHe and each day were
tested using an analysis of variance (ANOVA) with Tukey’s post hoc test and weighted
data using the standard deviation of pH measurements. The correlation between pH
gradient and tumour volume was tested using Pearson correlation.
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4.2.9

Histology

At the experimental endpoint, animals were sacrificed and perfused with 4%
paraformaldehyde (Sigma Aldrich, Miamisburg OH, U.S.A). Perfused rat brains were
paraffin embedded and sectioned to 5-µm-thick slices. Then rat brain slices containing
tumour were stained with hematoxylin & eosin (H&E), Ki67 and HIF1α. These slices
were scanned with an AxioImager Z1 Upright Microscope (Carl Zeiss Canada, North
York, ON, Canada). Those images were subsequently co-registered with the T2-weighted
MR images acquired at 3T using Slicer (Version 4.31, Surgical Planning Laboratory,
Brigham & Women's Hospital Boston MA, U.S.A.) with a custom software plugin.[29]

4.3 Results
Seven Wistar rats were used in this study; five animals survived to the last imaging time
point. The other two animals were sacrificed before the final imaging time point because
of neurological impairment related to tumour volume. All animals showed aggressive
tumour growth throughout the study, which is an expected feature of the C6 glioma
model.[17]
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Figure 4-2 The progression of intra- and extracellular pH of a representative C6 glioma.
Panels a) b) and c) present the T2-weighted images, and intra-and extracellular pH maps
of the rat brain at days 8 and 12. Tumours are contoured in magenta. d) Quantification of
changes of intra- and extracellular tumour pH. Statistical significance is annotated with
letters (measurements with different letters are significant at p < 0.05). e) Longitudinal
tumour volume measurements. Inter-observer variability was used for the error bar. A
large region of necrosis within the tumour is evident on day 12 in panel a). This animal
was sacrificed prior to the final imaging time point on day 15 due to neurological
impairment.
Two animals from the cohort were chosen to demonstrate the observed changes in pH
gradient of tumour cells. The first representative animal is shown in Figure 4-2. This
animal did not survive to the final imaging time point but was scanned on days 8 and 12.
Rapid tumour growth is evident by inspection of Figure 4-2a and quantified in Figure 42e. At day 12, the dark region within the tumour boundary on the T2-weighted image was
indicative of extensive necrosis. Maps of pHi and pHe at both imaging time points are
provided for comparison in Figures 4-2b and 4-2c and the average pHi and pHe for the
tumour is provided in Figure 4-2d. There was a statistically significant difference (p <
0.05) between pHi and pHe of the tumour at day 12. There was also a significant increase
in pHi of the tumour (p < 0.05) between days 8 and 12. However, there was no significant
change in pHe of the tumour (p ~ 0.11). A second representative case is shown in Figure
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4-3. This animal was scanned on days 8, 12 and 15 prior to sacrifice. This animal also
exhibited a rapidly growing tumour as shown in Figure 4-3a and quantified in Figure 43e. Again, pHi and pHe maps of the rat brain are shown in Figure 4-3b and c and average
pHi and pHe of the tumour are graphed in Figure 4-3d. Only at day 12 and 15, there was a
statistically significant difference (p < 0.05) between pHi and pHe within the tumour.
Tumour necrosis was not evident with T2-weighted MRI. Increased pHi within the tumour
was only significant (p < 0.05) at day 15. The pHe of the tumour was significantly
decreased (p < 0.05) at day 12 compared to day 8 but increased again by day 15.

Figure 4-3 The progression of intra- and extracellular pH of a representative C6 glioma.
Panels a) b) and c) present the T2-weighted images, and intra-and extracellular pH maps
of the rat brain at days 8, 12 and 15. Tumours are contoured in magenta. d)
Quantification of changes of intra- and extracellular tumour pH. Statistical significance is
annotated with letters. e) Longitudinal tumour volume measurements. Inter-observer
variability was used for the error bar.
Longitudinal changes in average pH gradient and tumour volume of all animals are
shown in Figure 4-4. Figure 4-4a shows the average pHi of tumours and contralateral
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brain on days 8, 12 and 15. Between days, there was no significant difference for
measured pHi within either tumour or contralateral brain tissue; however, tumour pHi was
significantly larger (p < 0.05) than contralateral brain at all days. Similarly, Figure 4-4b
shows the average pHe of tumours and contralateral brain on days 8, 12 and 15. There
was no significant difference detected on day 8 between tumour and contralateral tissue.
However, there were significant reductions (p < 0.05) in tumour pHe on day 12 and 15
and a significant increase (p < 0.05) in contralateral brain pHe on day 15. Significant
differences between tumour and contralateral brain pHe were observed on day 12 and 15.
Figure 4-4c illustrates the comparison between pH gradients in tumours and contralateral
brain tissue on days 8, 12 and 15. The pH gradient within tumours increased significantly
over the three imaging time points (p < 0.05). The pH gradient for contralateral brain
regions did not change significantly over this period but was consistently less than that
observed within the tumours. Lastly, figure 4d shows the average tumour volume for
days 8, 12 and 15. Tumour volumes significantly increased (p < 0.05) between imaging
time points.
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Figure 4-4 Longitudinal changes in cohort-averaged pH measurements. Panel a) &b)
shows intra- and extracellular pH in tumour and contralateral brain measured on days 8,
12 and 15. Panel c) compares cellular pH gradient between tumour and contralateral brain
at those same days. d) Average gross tumour volume measured from T2-weighted
imaging data. Inter-observer variability was used for the error bar. All statistical
significances (p < 0.05) are annotated with letters.
The association between tumour volume and pH gradient is plotted in Figure 4-5.
Averaging over all animals and time points, there was no significant correlation (p ~
0.26). However, when tumours with extensive necrosis were excluded, tumour volume
was correlated with pH gradient (p < 0.05) with a 0.715 Pearson coefficient.

86

Figure 4-5 Correlation plot comparing pH gradient and tumour volume. Tumours that
did not exhibit necrosis show a significant correlation (green line) between pH gradient
and tumour volume (p < 0.05, Pearson correlation = 0.72).
Histology for the second representative animal case is shown in Figure 4-6 with
corresponding pH and imaging data. The T2-weighted image showed no clear sign of
necrosis; however, necrotic parts of tumour were clearly distinguished from non-necrotic
parts by histology. The whole tumour region showed a relatively high pHi and low pHe
compared to contralateral brain tissue. H&E staining revealed an extremely high density
of cells within the tumour compare to normal brain. Further, necrosis was formed within
the core of the tumour. HIF-1 showed a higher expression in tumour compared to brain
tissue except within the necrotic region of brain. Similarly, Ki-67 staining showed greater
cellular proliferation in the tumour and no proliferation within the necrotic core and the
brain tissue surrounding the tumour.
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Figure 4-6 Histology of the 2nd representative animal shown in Figure 4-3. The first
column presents the tumour extent, pHi and pHe within the rodent brain. The tumour
margin is outlined in magenta. The second column contains histology including H&E,
HIF-1α and Ki-67 staining of tumour and brain tissue. The third column of images
contains magnified histology of the regions outlined by respective boxes in column 2.

4.4 Discussion
The purpose of this longitudinal study was to map and quantify the change in tumour pH
gradient using a rodent model of glioma. To the best of our knowledge, this is the first
study to sequentially measure both pHi and pHe at multiple time points during tumour
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progression in an in vivo model. This enabled a direct calculation of the cellular pH
gradient within the tumour and surrounding tissue. Knowledge of changes in cellular pH
gradient in tumours may be important for understanding biological changes in tumours
(metabolism, vascularization and proliferation) and informing on possible treatment
strategies (chemo- and radiotherapies).[8, 11]
The C6 rat glioma is a highly proliferating and aggressive solid tumour.[17] Tumour
volumes increase rapidly as seen in Figures 4-2, 4-3 and 4-4. Tumour imaging in some
animals suggested necrotic cores as shown in Figure 4-2a, which were confirmed by
histology (see Figure 4-6). Changes in tumour volume have been correlated to alterations
in tumour pH.[30] Hence, dynamic changes in tumour pH were expected commensurate
with tumour growth. Due to rapidly increasing tumour volumes, some animals did not
survive to the study endpoint. For animals with rapidly growing tumours, a reversal of pH
was expected as well as a correlation between tumour growth rate and change in tumour
pH.
In general, pHi and pHe within tumours and contralateral brain tissue were observed to
largely match what has been previously reported in literature. As shown in Figure 4-4a, at
day 15, tumour pHi (7.30±0.09) and tumour pHe (7.19±0.11) were similar to previously
reported values (pHi ~7.4 and pHe ~6.9)[7, 8, 10-12]. Similarly, measurements in
contralateral brain tissue, (pHi = 7.01±0.12 and pHe = 7.46±0.18) were also comparable
to previously reported values (pHi ~7.2 and pHe ~7.4)[7-9]. In addition, these in vivo
measurements confirmed the change in pH gradient direction for tumour cells compared
to those in contralateral brain tissue. However, it should be noted that the contralateral
brain does not represent ideal normal tissue. Elevated intracranial pressure due to the
large tumour burden would likely have an impact on brain tissue pH.[31] Although the
contralateral brain region did exhibit a consistently negative pH gradient, this region of
brain

would likely have been influenced

by intracranial hypertension

and

inflammation.[32] Measurements of the pH gradient (pHi – pHe) were observed to change
sign as early as day 8 in tumours. This was approximately the earliest time point where
tumour detection by MRI was reliable for this model.
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For each animal, longitudinal measurements of pHe and pH gradient within the tumour
showed a significant decreasing and increasing trend (respectively) as illustrated in
Figures 4-2d, 4-3d. However, the averaged pHi for all tumours did not show any
significant trend in time. The trend in tumour pHe suggests acidification of extracellular
space while the pHi of tumour cells remains constant during tumour progression. These
pH changes are a likely reason for the increase in tumour invasion and proliferation.
Conversely contralateral brain tissue showed no significant change until day 15 when
tumours had invaded the other hemisphere of the brain. At this last time point,
contralateral brain tissue was able to maintain pHi, but pHe homeostasis was no longer
balanced perhaps as a result of increased edema and reduced perfusion.
These tumours exhibited a large heterogeneity in pHi and pHe as demonstrated in Figures
4-2 and 4-3. These variations could be due to several biological factors. During tumour
progression, tumour metabolism undergoes extensive modification, but these metabolic
changes are often not homogenous.[33] Furthermore, the decrease in tumour pHe induces
inefficient and non-uniform vascularization[34] leading to further regional variation of
pHi and pHe.[35] Secondly, at the final time point, some tumours possessed necrotic
cores as shown in the histology of Figure 4-6. This can occur since C6 gliomas often
form a necrotic core as a result of rapid tumour growth and limited supply of
nutrients.[17] After the tumour cell undergoes necrosis, the integrity of the cellular
membrane is jeopardized and there is no longer a valid distinction between intracellular
and extracellular space.[36] Therefore, pHi and pHe measurements in regions of necrosis
would not properly represent tumour pH gradient. In this study, tumour necrosis could
not be reliably defined with T2-weighted images. Furthermore, with limited imaging
resolution and contrast, it was often difficult to identify necrotic regions prior to
experimental endpoint with histology. Never-the-less, the reversal of pH gradient was
observed at all time points when measurements were averaged over the entire tumour
volume identified by T2–weighted imaging even though pH measurements were not
statistically significant changing across time points.
For individual animals, the change in cellular pH gradient within the tumour was readily
apparent. Figure 4-2 presents a representative animal that died prior to the final imaging
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time point. For this case, the tumour grew exceptionally fast such that the animal suffered
significant weight loss and dehydration. Furthermore, rapid tumour growth led to
necrosis, which was observed as a hypo-intense region within the tumour boundary on
the T2-weighted image (Figure 4-2a). This was later confirmed as necrosis by histology.
For tumour regions where increasing pHi and decreasing pHe was observed, this was
likely a consequence of the tumour cells adapting to their microenvironment.[13] This
tumour also showed heterogeneous pHi and pHe throughout the tumour at day 12,
particularly in regions where necrosis was suspected compared to the non-necrotic
portion of the tumour. This emphasizes the dynamic changes in both tumour pHi and pHe.
Figure 4-3 showed another representative case in which the animal survived to the last
imaging time point. Unlike the previous case, longitudinal changes in tumour volume,
pHi and pHe were less substantial. In this case, pHe was significantly decreased for day 12
compare to day 8 but significantly increased at day 15. Importantly, this tumour was later
confirmed to have a substantial necrotic region by histology (see Figure 4-6), which is
likely a factor for the larger range of regional pH measurements. Using only T2-weighted
image data, it would be difficult to appreciate the full extent of the heterogeneity of the
tumour and its environment. Regional maps of pHi and pHe facilitate the visualization of
molecular and cellular changes linked to tumour progression in an individual animal.
A modest but significant correlation between tumour volume and pH gradient was
observed for this cohort (Figure 4-5). This correlation was only significant (p < 0.05)
when necrotic tumours were excluded. This correlation between tumour volume and pH
has been previously reported and that studies suggested a similar conclusion.[30, 37] This
correlation may explain increased tumour proliferation and invasion due to changes in
tumour microenvironment linked to pH.
The histology in Figure 4-6, further illustrates the effects of regional tumour pH.
Regional differences in pHi and pHe compared to contralateral brain corresponded well to
the distribution of HIF-1α and Ki-67 measured by histology. In glioma, HIF-1α is
upregulated and further induces metabolic remodeling.[38] Ki-67 is a marker for cellular
proliferation. Thus, this histology finding demonstrates a potential link between tumour
pH gradient, hypoxia and proliferation. Tumour heterogeneity is also speculated in both
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the pH maps and histology. The ability to detect and measure tumour proliferation is
important for the prognosis of these tumours. In addition, a priori knowledge of tumour
pH may be valuable for choice of appropriate chemotherapy.
In conclusion, this paper has demonstrated longitudinal mapping of pHi and pHe in a
rodent model of glioma. This is the first demonstration of non-invasive consecutive invivo measurement of pHi and pHe at multiple time points during tumour progression. This
study has shown that within a single tumour, there is a significant regional variation of
both pHi and pHe within tumour at a single time point. When these measurements were
averaged for all animals at each time point, there was no statistically significant
difference across time points. A statistical correlation between tumour volume and pH
gradient was observed for non-necrotic tumours. Highly proliferative regions of the
tumour can be observed by histology were associated with positive pH gradient. Regional
molecular information such as pHi and pHe provide important information about
longitudinal changes in the tumour environment. Knowledge of these changes may
ultimately be useful to guide therapeutic choice for treatment of GBM or to assess
treatment efficacy.
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Chapter 5
Summary and Future work

5

This thesis investigated the molecular imaging of tumour metabolism using
hyperpolarized

13

C magnetic resonance spectroscopic imaging (MRSI). Two important

aspects of tumour metabolism were assessed: pyruvate conversion to lactate and the
cellular pH gradient. The conversion of pyruvate to lactate is the final process of
anaerobic glycolysis. As described by the Warburg effect, solid tumours often prefer
energy production by glycolysis in the cytoplasm rather than more efficient oxidative
phosphorylation within the Krebs cycle of mitochondria. [1, 2] Since tumour progression
is correlated with lactate production, [3] the ability to measure this conversion can be
used to quantify tumour progression and early therapeutic effects. The cellular pH
gradient plays an important role in tumour proliferation and invasion. [4] Unlike healthy
tissue, tumours often exhibit a reversed pH gradient such that extracellular pH (pHe) is
lower than the intracellular pH (pHi). [5] Longitudinal measurements of changes in the
pH gradient within tumours could also be useful to understand tumour progression.
These aspects of tumour metabolism can be measured using hyperpolarized 13C magnetic
spectroscopy imaging. [1-13C]Pyruvate can be used to non-invasively determine the
lactate-to-pyruvate (Lac/Pyr) ratio in order to directly probe the conversion between
pyruvate and lactate in tumours.13C bicarbonate can used to directly measure pHe by
mapping the ratio of H13CO3- and 13CO2 concentrations after its injection and application
of the Henderson-Hasselbalch equation. Prior to injection into animals, [1-13C]pyruvate
and

13

C bicarbonate were hyperpolarized, which can produce a greater than 10,000-fold

signal increase for detection of metabolism with MRSI. [6] It is impractical to image
these probes without hyperpolarization, due to their low senstivity with MRI and limited
concentration in tissue. In addition, specialized MRI pulse sequences are necessary to
image these probes with a short acquisition time, which is dictated by the limited spinrelaxation time of hyperpolarized probes.
Furthermore, it was necessary to develop custom-made radiofrequency (RF) hardware for
hyperpolarized

13

C MRSI.

13

C MRSI produces regional molecular information while 1H
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MRI provides valuable anatomical context. As a result, sensitive dual-frequency RF
hardware was required to gather co-registered molecular and morphological imaging data
with high senstivity for signal detection. Thus a switch-tuned strategy for

13

C - 1H RF

hardware was designed and contructed. For optimum sensitivity and image homogeneity,
a TORO mode was included to improve signal detection.
In this thesis, a rat model of glioma was used to study tumour metabolism. This rodent is
an excellent model for preclinical imaging studies. It is relatively small and easy to
handle but it is also large enough for imaging with a clinical MRI system without
requiring higher-strength gradients to improve voxel size. Compared with mouse models,
intravenous injections through the tail vein are considerably easier. Moreover, rats better
tolerate the injected hyperpolarized imaging probes at larger volumes than smaller mice.
In this study the brains of rats were sterotectically implanted with glioma. A longitudinal
study was undertaken to assess the resulting tumour response to therapy. This tumour
model capitulates clinical progression and is an excellent system to study the assessment
of therapeutic response using hyperpolarized endogenous probes. These animal
experiments were peformed in accordance with relevant guidelines and regulations
stipulated by an animal use protocol approved by the University Council on Animal Care,
Animal Use Subcommittee at Western University.
Glioma is a highly aggressive and proliferating brain tumour. [7] It is an ideal model to
study tumour metabolism. As a highly proliferating tumour, glioma is very metabolically
active, specifically through glycolysis. Brain tissue, although also metabolically active,
prefers metabolism of pyruvate in the Krebs cycle, whereas in glioma pyruvate is
converted predominantly to lactate. This difference was exploited to detect and quantify
tumour response or progression after treatment. Increased glycolysis in the cytoplasm of
glioma cells leads to greater intracellular hydrogen ion and acid production and increased
ion transport to transfer these protons and metabolic acids to the extracellular space. This
maintains an alkaline pHi, at the expense of highly acidic pHe. While the brain is well
vascularized and perfused, this is not necessarily the case in the cores of brain tumours
where necrosis is often present due to hypoxia. [8] The combination of an acidic
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interstitial space and lack of perfusion gives tumour cells a proliferative advantage
compared to other cells, which aids in proliferation.
Clinical treatment of glioma involves surgical resection of the tumour, if possible and
radiotherapy followed by administration of chemotherapy to the patient. [9] In this study,
stereotactic surgery was omitted which is extremely difficult to perform on rodents.
Radiotherapy comprised of two fractions of 20 Gy, were administered to only the
hemisphere of the brain containing the tumour with a modified CT system. For
chemotherapy, 40 mg/kg of temozolomide (TMZ) was administered intraperitoneally for
5 days to mimic clinical practice. These therapies and their combination were chosen to
duplicate the clinical setting as much as possible so that the some of the imaging methods
and results learned through this longitudinal imaging study might eventually become
clinically relevant.

5.1 Construction and evaluation of a switch-tuned 13C –
1
H RF coil
Chapter 2 describes the construction a switch-tuned 13C – 1H birdcage RF coil system that
is capable of metabolic imaging of hyperpolarized 13C-enriched metabolic probes for coregistration with 1H MRI morphology. In addition, the imaging performance of the RF
coil was evaluated through comparison with identical single-tuned, 1H and

13

C birdcage

RF coils, which were constructed for that purpose. To further enhance RF receive
sensitivity, a 13C receive-only surface RF coil with active decoupling was also integrated
with the switch-tuned
system for

13

C – 1H RF system to produce a transmit-only, receive-only RF

13

C operation. The performance of the individual RF coils and the TORO

system were tested with specialized imaging phantoms at both 1H and 13C frequencies. A
fast gradient-recalled echo (FGRE) sequence was used for proton imaging of phantoms
and

13

C spectra were acquired using a FID-CSI sequence. B1 homogeneity was also

mapped using the Look-Locker method. The signal-to-noise ratio (SNR) achieved with
the switch-tuned coil in transmit/receive mode was 87% that of the single-tuned 1H coil.
For 13C imaging, the SNR for the switch-tuned 13C coil was 55% that of the single-tuned
coil. TORO operation of the switch-tuned coil with the surface coil increased SNR for by
a factor of 4.2 over transmit/receive operation of the switch-tuned coil alone. As figure 2-
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5 illustrates, the B1 map is homogenous over the entire coil volume except near its ends.
Finally the TORO RF and animal support systems were evaluated with animal imaging.
This system provided co-registered imaging data for both nuclei with sufficient SNR for
in vivo imaging experiments. Due to the additional circuit elements, the switch-tuned 13C
– 1H RF coil had inferior SNR compared to that of individual frequency RF coils.
However, the use of a surface coil with TORO operation greatly improved the observed
SNR. In vivo metabolic imaging of injected [1-13C]pyruvate in a rat model of glioma was
demonstrated using TORO operation. Two-dimensional

13

C spectral maps of pyruvate

metabolism were measured, which were inherently co-registered with 1H anatomical
images.

5.2 Quantifying early therapeutic response using
hyperpolarized [1-13C]pyruvate MRSI
Chapter 3 demonstrates the use of hyperpolarized 13C MRSI to assess therapeutic efficacy
in a preclinical tumour model. [1-13C]pyruvate was used to monitor early changes in
tumour metabolism based on the Warburg Effect. High grade malignant tumours exhibit
increased glycolytic activity and lactate production to promote proliferation. [10] A rat
glioma model was used to explore altered lactate production after therapy as an early
imaging biomarker for therapeutic response. Rats were surgically implanted with C6
glioma cells and separated into four groups: no therapy, radiotherapy, chemotherapy and
combined therapy. Animals were imaged serially at 6 different time points (days 7, 12,
15, 18, 21, 24 after the surgery) using hyperpolarized [1-13C]pyruvate MRSI and
conventional 1H imaging. Using hyperpolarized [1-13C]pyruvate MRSI, alterations in
tumour metabolism were detected as changes in the conversion of lactate to pyruvate
(measured as the Lac/Pyr ratio) and compared to the conventional method of detecting
therapeutic response using anatomical tumour volume measurement. In addition, the
Lac/Pyr ratio was correlated with tumour growth rate. Hypoxia staining was performed at
experimental endpoint and compared with the Lac/Pyr ratio map. Each therapy group
expressed different characteristic changes in tumour metabolism. The group that received
no therapy showed a gradual increase of the Lac/Pyr ratio within the tumour. The
radiotherapy group showed large variations in tumour Lac/Pyr ratio. The chemo- and
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combined therapy groups showed a statistically significant reduction in tumour Lac/Pyr
ratio, however only the combined therapy was capable of suppressing tumour growth,
which resulted in low endpoint mortality. A prompt reduction in the Lac/Pyr ratio was
very apparent after therapy. However, measurements of tumour volume were not useful
for establishment of therapeutic response until a much later time point. The Lac/Pyr ratio
showed a significant correlation with tumour growth rate; however, it was not
significantly correlated with tumour volume. Thus, Lac/Pyr ratio is potentially related to
the growth of tumour rather than tumour volume. Regional differences in the Lac/Pyr
ratio were consistent with hypoxia histology. Hyperpolarized magnetic resonance
spectroscopic imaging of the metabolism of [1-13C]pyruvate was able to detect a
reduction in the Lac/Pyr ratio as early as two days post combined chemo- and
radiotherapies. In conclusion, metabolism of hyperpolarized [1-13C]pyruvate has been
demonstrated as a non-invasive biomarker for assessment of therapeutic response.

5.3 Longitudinal Measurement of pH gradient
Chapter 4 reports the first longitudinal measurement of intracellular/extracellular pH
gradient using non-invasive magnetic resonance imaging in a C6 rat glioma model. The
acid-base balance in the brain is tightly controlled by endogenous buffers such as
bicarbonate and phosphate. Tumours often express a positive pH gradient (pHi – pHe) in
contrast to a negative gradient in normal tissue. [8] An alkaline pHi in tumour cells
increases the activity of several metabolic enzymes that drive cellular proliferation. [4] In
contrast, an acidic pHe is established due to increased lactic acid production and the
subsequent active transport of protons out of the cell. [11] The pHi was mapped with
chemical exchange saturation transfer (CEST) and hyperpolarized 13C bicarbonate MRSI
was used to determine regional pHe. Rats were surgically implanted with C6 glioma cells
in the brain. pHi and pHe were mapped in the tumour tissue and contralateral brain tissue
at days 8, 12 and 15 post implantations. After sacrifice, rat brains were stained for
histology including haematoxylin and eosin, HIF-1α and Ki-67. Compared to
contralateral brain tissue, the pHe in tumours was more acidic, whereas the pHi within
tumour cells was more alkaline leading to an increase in the pH gradient compared to
contralateral. Longitudinal measurements of the average pH gradient for all rats is shown
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in Figure 4-4. Overall, the averaged pH gradient in the tumour changed from 0.02±0.11
to 0.10±0.21 then 0.19±0.16. Conversely the pH gradient of contralateral brain tissue
changed from -0.44±0.16 to -0.25±0.21 then -0.33±0.25. The observed pH gradient was
consistently larger in tumour than contralateral tissue. The pH gradient of tumours
increased during tumour growth and also the heterogeneity of tumour pH was apparent at
later time points. These regional measurements may be useful to assess therapeutic
response

and

predict

local

areas

of

treatment

resistance.

Overall,

the

intracellular/extracellular pH gradients in this rat glioma model were non-invasively
measured to a precision of ~0.1 pH units at three time points. Since most therapeutic
agents are weak acids or bases, a priori knowledge of the pH gradient may help guide
choice of therapeutic agent.

5.4 Future work
A TORO RF system was developed to provide a sensitive detection system for

13

C

MRSI. RF sensitivity could be extended over a larger volume than that provided by the
single surface receive coil by development of an RF receive array. Although an
individual surface RF coil has high sensitivity, this is only the case over a limited region.
In theory, the SNR of a coil array is increased by √𝑁 where N is the number of surface
coils. Furthermore, imaging can be accelerated using parallel imaging techniques. If there
is a sufficient coverage of the imaging volume by the array coil, spatial information of the
signal can be deduced by the weighting of signals from multiple surface coils. The
drawback of a coil array is that design and construction of the array coil is far more
complicated than for a single surface coil. Moreover, multiple receive channels are
required. Currently the multi-nuclear receive hardware at the GE Discovery MR750 3.0 T
is limited to eight channels. Receive arrays are typically operated in TORO mode with a
volume transmit coil.
In chapter 3, rat glioma was imaged for up to 24 days after tumour implantation. For
radiotherapy and combined therapy, survival outcomes of these groups were
inconclusive. Tumour volume was not significantly altered by therapy. Since glioma is
known to recur despite therapy [12], it is possible that a subsequent increase in the
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Lac/Pyr ratio might be observed in a treated tumour in a longer longitudinal study. This
would be an important finding, demonstrating a potential prognostic capability of this
imaging method. Other hyperpolarized

13

C probes can be used to quantify more aspects

of tumour metabolism. For instance, [1, 4-13C2]fumarate can be used to detect apoptosis.
Increased [1,4-13C2]malate production from [1,4-13C2]fumarate has been observed in
treated lymphoma cells after injection of hyperpolarized fumarate. This is likely a result
of cellular necrosis suggesting that formation of malate from fumarate may be an in vivo
biomarker for tumour cell death and response of tumours to treatment. [13] However, it
may be difficult to determine if and when an optimum time exists for in vivo imaging of
this process due to the nature of apoptosis.
In chapter 4, MRI techniques were used to quantify the cellular pH gradient in tumours.
Using these combined methods, a reversal of the pH gradient was observed in tumours
compared to healthy brain tissue. Some chemotherapy drugs are effective only within a
limited pH range. It would be informative to know in advance, how different therapies
might be affected by the tumour microenvironment including intracellular and
extracellular pH.
At this juncture, almost all hyperpolarized

13

C imaging research has been demonstrated

using cell cultures or animal models. [14, 15] [14, 15] [14, 15] [14, 15] [14, 15] [14, 15]
[14, 15] [14, 15] [14, 15] [14, 15] [14, 15] As basic research continues to develop the
foundation

for

eventual

clinical

translation,

manufacturers

have

developed

hyperpolarization apparatus compatible with human use. A small number of these
systems are currently being used for first-in-kind experiments and early clinical trials.
[14, 15] The use of

13

C-enriched endogenous substrates does not pose any significant

toxicity or radiation exposure. No dose-related problems are expected for human
imaging. With the advent of next-generation polarization technology, successful adoption
in the clinic will require pre-clinical research such as that presented in this thesis. This
will provide important information such as data to guide human dose, well-characterized
biomarkers for non-invasive detection and assessment of disease and a proven ability to
guide therapy.
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support hardware for hyperpolarized magnetic resonance imaging using healthy animals.
This early research established that the RF hardware had sufficient sensitivity for in vivo
experiments. It also established our ability to hyperpolarize endogenous compounds for
injection as contrast agents and safely inject them into the tail veins of rats and rapidly
image metabolism. We were also able to gauge imaging signal-to-noise ratio which
determines the spatial resolution of our metabolic imaging experiments. Our imaging
hardware is being used for all hyperpolarized preclinical imaging experiments at Robarts.
2) From early experiments we were able to determine the change in lactate conversion
from pyruvate in response to radio- and chemotherapies. This information allows us to
calculate accurate cohort numbers for our longitudinal studies.
3) We have observed significant changes in tumour hypoxia using metabolic imaging of
hyperpolarized pyruvate as early as two days post therapy. This provides a much earlier
assessment than changes in tumour volume measured from MRI or CT.
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4) Early experiments using hyperpolarized 13C bicarbonate have demonstrated our ability
to measure pH in solid tumours. These experiments have provided useful data for 7
research articles, the renewal of a research grant from the Ontario Institute for Cancer
Research, two research grants from Cancer Care Ontario and a funding application to the
Canadian Institutes for Health Research, which is still pending.
The 3Rs
Reduction: Our preliminary research has allowed us to refine our surgical techniques and
animal care to reduce animal mortality. We also have established animal numbers to
power our statistical comparisons between animal cohorts. Our experiments require
cohort numbers of approximately eight animals per treatment group to establish
significance between groups. We are requesting an additional four animals based on our
experiences to date to replace those animals that do not survive to the experimental
endpoint (if necessary).
Replacement: We are studying the response of solid tumours to realistic clinical treatment
as a first step to eventual clinical translation and as such, we require a realistic tumour
model. The C6 rat glioblastoma is an excellent experimental model for our research. The
tumours are precisely located through stereotactic intracranial implantation and grow
with relative speed and predictability from animal to animal. These tumours have good
contrast compared with healthy brain tissue with magnetic resonance imaging. Their
location within the skull provides improved tumour location and reduced image artefact
from animal motion.
Refinement: We are constantly improving our experimental apparatus and imaging
methods with an aim to improved imaging results. This will decrease the number of
animals required for our studies. We are also developing new formulations for
hyperpolarized probes, which will produce improved imaging results with decreased
injected dose.
Using non-scientific language, please describe the project's purpose, expected
benefit, and a brief summary of your work with the animal model(s).
Please be aware that in the event of communications with Western Media Relations
and the PI is not available, this summary will be sent to Western Media Relations.
Molecular imaging is a rapidly developing field, which non-invasively visualizes cellular
function such as metabolism. Our research has focused on development of novel
molecular imaging probes for magnetic resonance imaging (MRI) with a specific
emphasis on application to cancer imaging. Therapeutic choice for an individual cancer
patient relies on invasive tumour sampling. For many targeted agents, molecular
assessment is particularly important to both apply these agents to cancers that are most
likely to respond and avoid treatments that are unlikely to be effective. Sadly, predictive
biomarkers are not perfect prognosticators of therapeutic response or failure for a given
agent in a particular patient and treatment assessment often relies on longitudinal
measurements of changes in tumour size. Significant changes in tumour size can take
months to become apparent if at all. Molecular imaging has the potential to non-
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invasively assess subtle changes in disease. For cancer, it can assess the evolution of the
tumour microenvironment, determine the potential for tumour proliferation and, perhaps
most importantly, provide prompt evidence for early responses versus non-responses
during ongoing treatment.
Since MRI is a valuable diagnostic imaging tool capable of morphological and functional
imaging with high spatial resolution and is the standard of care for assessment of most
solid tumours, the added capability to assess molecular function is an important
development, particularly for cancer research. For example, our preclinical research is
demonstrating the ability to measure metabolic changes in the tumour such as hypoxia as
soon as one day after initiation of therapy. This research using hyperpolarized metabolic
imaging of hyperpolarized 13C-enriched compounds has produced seven peer-reviewed
research articles and 17 conference abstracts over the past four years. In addition, a recent
oral presentation of one of my PhD student’s thesis entitled “Molecular imaging of tumor
metabolism: a longitudinal study of tumour response to therapies using hyperpolarized
13
C pyruvate” received a Magna Cum Laude Merit Award (top 5%) at the 2014 Scientific
Meeting of the International Society for Magnetic Resonance in Medicine in Milan, Italy.
The next steps for our hyperpolarized imaging research is to investigate additional probes
of the tumour microenvironment. Our initial experiments have focused on pyruvate
metabolism and its role in assessing hypoxia. We are currently interesting in assessing
changes in pH, which tumours exploit for proliferative advantage. Using hyperpolarized
13C bicarbonate, we plan to non-invasively measure extracellular pH and compare that
with the intracellular pH assessed through chemical exchange saturation transfer (CEST)
magnetic resonance imaging in tumour cells. Cellular necrosis in response to therapy can
also be measured through conversion of hyperpolarized fumarate to malate as cellular
walls break down. These three important biomarkers of the tumour microenvironment
(hypoxia, pH and cellular necrosis) will be studied simultaneously in a rat model of
glioma to look at their prognostic potential for early assessment of treatment response
and longer term treatment outcome in extended longitudinal studies.
We are working with John Ronald to modify our brain cancer cell line for in vivo animal
experiments. We have engineered these cells so that they are produce a fluorescent green
protein which makes the viable tumour cells much more visible under histology. In
addition, the cells produce an enzyme known as luciferase, which can be used for
bioluminescence imaging (BLI). Our animals are injected with a small amount of a
compound known as luciferin. The luciferase produced by living tumour cells cause a
chemical reaction with the luciferin that produces light. The amount of light that we
measure with BLI is proportional to the number of living tumour cells. This allows us to
non-invasively measure tumour burden in longitudinal studies of therapy. This is our
gold-standard against which we can compare our other methods such as metabolic
imaging of pyruvate, measurements of pH and cellular necrosis.
GLOSSARY OF TERMS - Identify each individual scientific term and abbreviation
using CAPITAL LETTERS, and then briefly define each term to be referenced in
any section of this protocol.
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e.g. ALLELE - The genetic variant of a gene responsible for the different traits of
certain characteristics and genetic diseases.
MRI - Magnetic Resonance Imaging.
13
C - A naturally occurring non-radioactive isotope of carbon (1.11% natural abundance).
HYPERPOLARIZATION - A technique for enhancing MRI signal strength by factors of
up to 100,000.
PYRUVATE - An endogenous intermediate in carbohydrate metabolism.
BICARBONATE - An endogenous compound used to measure in vivo pH with
hyperpolarized imaging.
CEST - Chemical exchange saturation transfer. This a magnetic resonance imaging
technique that is used to measure intracellular pH. This is a non-invasive imaging method
that does not require injection of a contrast agent.
GLIOBLASTOMA or GLIOMA - A glioma is a type of tumor that starts in the brain or
spine, more specifically the definition of glioma is a primary brain tumor that originates
from the supportive cells of the brian, called glial cells. Glial cells are the most common
cellular component of the brain There are five to ten times more glial cells than neurons.
A Glioblastoma is a particular type of Glioma (Astrocytoma).
FUMARATE - An endogenous intermediate in the citric acid cycle (krebs cycle).
MOLECULAR IMAGING - a non-invasive means to visualize cellular function such as
metabolism.
BLI - Bioluminescence imaging is a means of measuring the biodistribution of cells that
have been engineered to produce light after injection of a contrast agent.
Luciferin -is a light-emitting compound which is injected into animals to generate
bioluminescence. Cells in these animals, which produce the enzyme luciferase cause a
chemical reaction with luciferin producing light that can be imaged by BLI.
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http://www.ccac.ca/Documents/Standards/Policies/Scientific_merit_and_ethical_review_
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Do you wish to provide a funding peer review assessment, which may be considered
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No
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relevant to the work outlined in this AUP.
If this is a research AUP, attach an OUTLINE for scientific merit reviewers that
provides sufficient information that another scientist working in the same field of
study could effectively review this AUP's scientific merit, below. PIs may utilize
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whichever format best describes its scientific merit, e.g. background, rationale,
hypothesis, objectives, experimental procedures
Using only key words, specify the animal models and procedures described within
this AUP.
Research/ Anaesthesia/ Imaging/ Stereotaxic Surgery/ Tumour Cell Injections/ Analgesia/
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111

Curriculum Vitae
Education
• Ph.D. Medical Biophysics, 2010 Sept ~ Present, University of Western Ontario,
London, ON. Concentration: Hyperpolarized 13C metabolic imaging
• B.Sc. Specialist in Biophysics, 2006 Sept ~ 2010 Apr, University of Toronto,
Toronto, ON.
Publications (1st Author)
1. Heeseung Lim, Thind K, Alejski A, Martínez F, Scholl TJ, Construction and
Evaluation of a Switch-Tuned 13C - 1H Birdcage Radiofrequency Coil for Imaging
the Metabolism of Hyperpolarized 13C-Enriched Compounds. Journal of Magnetic
Resonance Imaging, 2014. 40(5): p. 1082-1090.
2. Heeseung Lim, Martinez-Santiesteban F, Jensen M, Chen A, Wong E, Scholl TJ,
Monitoring changes in tumour metabolism in response to therapy using
hyperpolarized 13C MRSI in a preclinical model of glioma. Scientific Reports (in
revision).
3. Heeseung Lim, Albatany M, Bartha R, Scholl TJ. “Longitudinal Monitoring of
Tumour pH Gradient with MRI” NMR in Biomedicine (in preparation).
Publications (Other)
1. Martinez-Santiesteban FM, Dang TP, Heeseung Lim, Chen AP, Scholl TJ, T1
Nuclear Magnetic Relaxation Dispersion of the Sodium and Cesium Salts of
Hyperpolarized 13C-Bicarbonate. NMR in Biomedicine (accepted).
2. Thind K, Jensen MD, Hegarty E, Chen AP, Heeseung Lim, Martínez F, Van Dyk
J, Wong E, Scholl TJ, Santyr GE, Mapping metabolic changes associated with
early Radiation Induced Lung Injury post conformal radiotherapy using
hyperpolarized 13C-pyruvate Magnetic Resonance Spectroscopic Imaging.
Radiotherapy and Oncology, 2014. 110(2): p. 317-322.
3. Mallett CL, Heeseung Lim, Thind K, Chen Y, Ribot EJ, Martínez F, Scholl TJ,
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